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Glycosylation plays an important role in biology but its impact on the quality and 
biologics manufacturing is just beginning to be appreciated. Studies have shown that 
the sialylation of glycoproteins result in better circulatory half-life and therefore 
higher efficacy. In the production of erythropoietin (EPO), almost 80% that is 
produced is discarded due to insufficient sialylation. The research documented in this 
thesis centers upon the improvement of sialylation of EPO in a glycosylation mutant 
isolated through lectin selection. It is proposed that this cell line would result in 
improving the way EPO and possibly other recombinant therapeutic glycoproteins are 
produced.    
 
In this research, the characterization of glycosylation mutants that survived lectin 
selection using Ricinus communis agglutinin-I (RCA-I), it was demonstrated that the 
lectin only selected CHO mutants that were deficient in N-
acetylglucosaminyltransferase I (GnT I). The mutations found in these glycosylation 
mutants shed more light on the structure and function of the glycosylation enzyme. 
One of these cell lines was named CHO-gmt4.  
 
Interestingly, the restoration of functional GnT I in CHO-gmt4 cells seemed to enable 
the expression of EPO that was better sialylated than the wild-type CHO-K1 cells. 
This was observed in all the glycosylation mutants isolated from RCA-I selection. 
The overexpression of GnT I in CHO-K1 cells did not result in the same improvement 
in sialylation. Further, the sialylation of transiently expressed EPO-Fc fusion protein 
was also shown to be better when co-expressed with GnT I using CHO-gmt4 cells. 
 ix 
Transiently expressed EPO-Fc in CHO-gmt4 cells with functional GnT I restored 
contained 23% more sialic acid than CHO-K1 expressed EPO-Fc as quantified by the 
thiobarbituric acid assay. HPAEC-PAD analysis also showed that the improvement in 
sialylation over wild-type expressed recombinant EPO-FC was due to increased 
proportion of tri- and tetra-antennary sialylated structures. The improvement in 
sialylation was also observed in the stable co-expression of EPO and GnT I.  
 
In order to generate an EPO- producing cell line with a better titer, the CHO-gmt4 cell 
line was then gene-edited using zinc-finger nuclease to knock out dihydrofolate 
reductase gene to enable subsequent gene amplification. The successful knock out of 
DHFR generated a new cell line, CHO-gmt4D. CHO-gmt4D was stably transfected 
with both EPO and GnT I and after several rounds of methotrexate amplification, a 
series of clones that produced EPO with superior sialylation was generated.  
 
One of these clones, named CHO-gmt4D-EPO-GnT I was cultured in an industrial 
bioprocess with perfusion-culture based bioreactor and the resulting EPO was purified. 
The bioreactor studies showed that the superior sialylation of EPO was maintained 
Using HPAEC-PAD, sialic acid quantification and MALDI-TOF analyses, the 
purified EPO was shown to contain better sialylated EPO than the existing industrial 
clone that was used for regular EPO production in that bioprocess.  
 
These results demonstrate that the CHO-gmt4 cell line can be applied in the 
production of recombinant EPO with more superior sialylation, thus paving the way 
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Chinese hamster ovary cells (CHO) cells are the workhorse of the biologics industry. 
CHO cells-produced biologics have seen tremendous growth in the last two decades. 
The biologics that are produced using CHO cells alone is more than US$30 billion 
worldwide and seven, out of the top ten best selling biologics (Huggett and 
Lähteenmaki, 2012), are produced in CHO cells. The first recombinant protein 
produced in CHO cells was tissue plasminogen activator or Activase and was 
approved in 1987 for therapy. Since then, CHO cells have had a proven track record 
in being safe hosts for producing glycoproteins, and that the resultant glycosylation of 
this therapeutics are compatible with humans. Furthermore, CHO cells are naturally 
resistant to over 44 human viruses in that these viruses do not replicate in CHO cells. 
With so many benefits, it is not difficult for one to see the tremendous value in 
continuing research on this cell line.  
 
The importance of the compatibility of the recombinant protein glycosylation in 
humans is becoming increasingly apparent as demonstrated by the immunogenicity of 
plant expressed recombinant proteins (Bardor et al., 2003) and the administration of 
Cetuximab leading to patients suffering from anaphylaxis (Arnold and Misbah, 2008). 
Many sugar epitopes such as galactose-alpha-1,3-galactose (alpha-Gal), N-
glycolylneuraminic acid (Neu5Gc) and hyper-mannosylated glycan structures are now 
known to be immunogenic. CHO cells have been shown to produce recombinant 
protein with N-glycosylation largely similar to those of human proteins. They produce 
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complex and hybrid N-glycan structures on a large range of recombinant glycoprotein 
therapeutics that have not elicited immunogenic reactions due to the glycosylation 
present.  
 
Recombinant protein glycosylation has also shown that it has a significant role to play 
in the efficacy of the therapeutic protein by influencing the circulatory half-life of the 
drug through the presence of sialic acid (Egrie and Browne, 2000). This is due to the 
presence of an asialoglycoprotein receptor in the liver that is responsible for removing 
glycoproteins that might have galactose epitopes exposed due to the loss of sialic acid. 
This receptor aids in the endocytosis of the therapeutic drug and its subsequent 
clearance.  
 
The absence of fucose in monoclonal antibody therapy has been shown to be more 
effective through better binding to the Fcγ receptors and hence higher antibody-
dependant cell-mediated cytotoxicity.  
 
The understanding of glycosylation has been aided in part through the study of 
glycosylation mutants as it is through these mutants and their phenotypes that many 
glycosylation genes have been cloned through gene complementation tests. 
Furthermore, the discovery of new mutants might lead to the ability to produce certain 
therapeutic proteins that require that require specific glycosylation like the absence of 
fucose or terminal mannose. 
  
It is within this context that this work began with the characterization of a set of 
glycosylation mutants that were isolated with cytotoxic plant lectin, Ricinus 
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communis agglutinin-I or RCA-I. It was later observed that mutants that were isolated 
through this method could possibly produce glycoproteins with superior sialylation. 
Thus began this work to give a proof of concept that the glycosylation mutant could 
indeed produce better sialylation consistently and that this phenomenon would be 
maintained in an industrial setting.  
 
1.2 Thesis objectives 
 
This main aims of this thesis are:- 
  
1) To characterize the mutants that have been isolated using RCA-I 
2) Demonstrate the high level of sialylation of the model glycoprotein, 
erythropoietin, through transient and stable expression.  
3) Generate a high producing EPO expressing clone through gene amplification 
and use as a production cell line in an industrial bioreactor.  
 
1.3 Thesis organization 
 
This thesis consists of eight chapters.  
 
Chapter 1 describes the background and aims of the research.  
Chapter 2 presents a literature review of (i) Glycosylation (ii) The impact of 
glycosylation on recombinant production of therapeutic glycoproteins (iii) 
Glycosylation of recombinant proteins in different industrial host cell lines (iv) 
Strategies for improving sialylation in CHO cells (v) N-acetylglucosaminyltransferase 
I (GnT I) and glycosylation mutants with defective GnT I and (vi) Erythropoietin. 
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Chapter 3 is a record of the materials and methods used for this research. 
Chapter 4 is about the characterization of glycosylation mutants that were isolated 
through lectin selection. 
Chapter 5 demonstrates the superior sialylation of EPO produced by GnT I mutants 
after restoration of the GnT I function.  
Chapter 6 shows how the DHFR gene was knocked out of CHO-gmt4 cells and 
details the characterization of that cell line.  
Chapter 7 describes the amplification process and bioreactor run results.  




CHAPTER 2   LITERATURE REVIEW 
 
 
2.1 Glycosylation  
 
Glycosylation is a post-translational modification that attaches a sugar moiety to the 
protein backbone as the protein is being translated. There are two main types of 
glycosylation N-glycosylation and O-glycosylation. N-glycosylation attaches a 
preformed oligosaccharide onto the protein when the consensus sequence N-X-S/T, 
where X can be any amino acid except proline. In contrast, there is no consensus 
sequence for O-glycosylation, and the initial attachment of N-acetylgalactosamine to a 
serine or threonine is followed by the elongation of this sugar chain by various 
enzymes to give many different glycan forms.  
 
N-glycosylation is a common post-translational process, which takes place in 
eukaryotic cells and archaea. The initial mechanisms for N-glycosylation is largely 
conserved through archaea to mammalian systems and the process of this post-
translational modification are dependent on a set of enzymes found in the 
endoplasmic reticulum and the Golgi. This set of enzymes can be broadly classified as 
the nucleotide sugar transporters, glycosyltransferases and glycosidases. Nucleotide 
sugar transporters are necessary for transporting nucleotide sugars that are 
synthesized in the cytosol into the lumen of the ER and Golgi in which the 
glycosyltransferases reside. Glycosyltransferases then catalyze the attachment of the 
sugar molecules onto the acceptor carbohydrate structure. Glycosidases are 
responsible for trimming the oligosaccharide structure.  
 
 6 
There are ten monosaccharides that are involved in N-glycosylation.  Of these ten, 
seven are utilized in mammalian N-glycosylation : N-acetylglucosamine (GlcNAc), 
N-acetylgalactosamine (GalNAc), galactose (Gal), N-acetylneuraminic acid (Neu5Ac) 
or otherwise known commonly as sialic acid, mannose (Man) and fucose (Fuc). Other 
monosaccharides have been known to be incorporated into glycan structures but are 
of non-human origin: Glucoronic acid (GlcA), N-glycolylneuraminic acid (NeuGc), 
xylose (Xyl) (Bertozzi and Rabuka, 2009). 
            
N-glycosylation begins with the synthesis of a lipid-linked-oligosaccharide (LLO), 
which is formed, first by the addition of two GlcNAc and five Man sugars to the 
dolichol-phosphate lipid molecule. Initially embedded in the membrane on the 
cytosolic side, the LLO then flips into the lumen of the ER by an unknown 
mechanism where another four Man sugars and three Glc sugars are added to arrive at 
the final glycosylation precursor, Glc3Man9GlcNAc2-DolP. 
 
This precursor is then transferred from the lipid carrier onto the asparagine residue in 
the nascent protein whenever the asparagine residue is situated within a consensus 
sequence, N-X-S/T, where X can be any amino acid except proline.  
 
The glucose residues are trimmed whilst the protein undergoes folding and upon 
successful refolding, the protein is packaged and transported into the Golgi where the 
oligosaccharide, now containing a nine-mannose structure is further trimmed and the 
structure is further elaborated upon by the addition of N-acetylglucosamine to 
different extents of branching up to a maximum of four branches. Terminal sugars 
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such as galactose and finally sialic acid are also added in addition to a fucose, which 
is attached to the N-acetylglucosamine proximal to the asparagine residue.  
 
2.2 The impact of glycosylation on recombinant production of therapeutic 
glycoproteins 
 
Since the commercial production of insulin, the industry has seen a phenomenal rise 
in the proliferation of different biotherapeutics that are expressed heterologously. The 
drive behind the need to use heterologous expression systems arises from the 
inadequate amounts that can be purified from natural sources for therapeutic doses. 
Many of these therapeutic proteins use bacterial expression systems, however, the 
presence of post-translational modifications on some of these products requires the 
use of mammalian expression systems.  
 
Several aspects of the oligosaccharide structure have been investigated and reports 
have shown that the sugars play an important role in augmenting the action of the 
protein that it is attached to. Glycosylation has an impact on the stability, circulatory 
half-life, solubility, physicochemical properties and immunogenicity of the 
recombinant protein. The incomplete glycosylation or the absence of glycosylation 
might lead to changes in the stability of the glycoprotein, affecting the way the protein 
would be stored and how its efficacy would be affected with longer term storage. For 
example, EPO expressed in E. coli is more susceptible to denaturing conditions and 
precipitates in solution at a lower temperature compared to the glycosylated asialo 
form of EPO (Narhi et al., 1991). The removal of the glycosylation sites in EPO by 
mutating Asn38 and Asn83 as well as a triple mutation at Asn24, Asn 38 and Asn 83 
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to glutamine led to poor secretion in CHO and Cos-1 cells (Delorme et al., 1992), 
suggesting that the folding and stability of the protein is highly dependant on 
glycosylation.  
 
Therapeutic antibodies have been shown to possess increased binding to FcγRIII 
receptors of up to 50-fold (Iida et al., 2006) due to a lack of fucose in the N-glycan 
present in the Fc-portion of the antibody. This has been shown to enhance the 
antibody-dependent cellular cytotoxicity (ADCC) up to 100-fold (Yamane-Ohnuki et 
al., 2004).  
 
The presence of sialic acid in N-glycans in non-antibody glycoprotein therapeutics has 
been shown to greatly influence the circulatory half-life of therapeutic glycoproteins. 
The absence of sialic acid or incomplete capping of the terminus of N-glycans, 
leading to the decreased serum half-life has been shown for several proteins. The half-
life of gonadothropin is reduced from 1.5 hours to 3 min (Batta et al., 1978), and for 
erythropoietin, the circulatory half-life is reduced from 3 hours to 2 min (Fukuda et al., 
1989). Several other reductions in circulatory half-life in other therapeutic proteins 
have been reviewed (Ngantung et al., 2006). Sialic acid caps the N-glycans and masks 
the galactose residue from asialoglycoprotein receptors present in the liver ( Morell et 
al., 1971) . When the galactose residues are exposed, the endocytosis-mediated 
removal by galactose specific receptors in the hepatocytes results in the fast removal 
of the therapeutic glycoprotein from circulation, resulting in reduced efficacy. The 
efficacy of the drug has also been shown to correlate with the number of sialic acids 
present in the N-glycans of recombinant therapeutic proteins (Egrie and Browne, 
2000). Incomplete processing of the N-glycan structure may also lead to the exposure 
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of other sugar residues such as mannose and GlcNAc to other lectin-receptors present 
in other cell types.  
2.3  Glycosylation of recombinant proteins in different industrial host cell 
lines 
 
2.3.1  Bacteria hosts 
 
The production of proteins in bacteria host cells such as Escherichia coli is desirable 
because of the fast growth rate and cost-effectiveness due to the simpler media 
components. However, E. coli does not possess any glycosylation machinery that will 
result in the proper glycosylation of protein therapeutics. As such, it is mainly used 
for the production of proteins that do not contain N-glycosylation sites such as insulin 
and growth hormones.  
 
2.3.2 Yeast cells 
 
Yeast cells have also been mostly used for the production of proteins that do not 
require glycosylation such as insulin and growth hormones. Yeast cells  possess a 
secretory mechanism, which would greatly simplify purification processes as 
compared to bacteria expression systems. Yeast cells have basic glycosylation 
machinery that conserves the process whereby the N-glycan precursor that is 
transferred from dolichol-phosphate and is processed by glucosidases I and II and 
α1,2-mannosidase to give the structure Man8GlcNAc2. This structure on the protein is 
transferred to the Golgi apparatus where the subsequent elongation of the N-glycan 
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with α1,6-linked Man residues by OCH1 mannosyltransferase results in 
oligomannose structures often containing 50 or more Man residues. Depending on the 
yeast species, other extensions such as phosphomannose groups may be added. The 
yeast glycan structures are not suitable for human protein production as the clearance 
rate of oligomannose structures is high and may also result in immunogenic reactions 
(Arnold and Misbah, 2008). 
 
The first steps towards trying to humanize the yeast glycosylation machinery was 
through the successful generation of a strain of Saccharomyces cerevisiae which 
expressed the glycan structure Man8GlcNAc2 through the elimination of OCH1 and 
MNN1(Nakanishi-Shindo et al., 1993). More significant was the strains of Pichia 
pastoris which produced Man5GlcNAc2 through the selection and expression of 
suitable α1,2-mannosidase using combinatorial library screening (Choi et al., 2003).  
Through the same approach of library screening of and introduction of 
glycosyltransferase fused to mannosidase yeast localization signals, the same group 
arrived at a strain of Pichia pastoris capable of producing galactosylated complex N-
glycans. Finally, the biosynthetic pathway for sialic acid and α2,6-sialyltranferase 
was introduced arriving at a strain of Pichia pastoris which was able to produce N-




2.3.3 Insect cells 
 
Insect cells such as SF9 have been studied with the hope that they can be used in the 
production of biologics, and they have been shown to be successfully infected with 
baculovirus and express several glycoproteins in a cost efficient bioprocess(Altmann 
et al., 1999). Insect cells possess a basic set of glycosylation machinery which differs 
from the yeast glycosylation machinery by the ability to trim the oligomannose 
structure and add the first GlcNAc (Altmann et al., 1995).  
 
However, this GlcNAc is then trimmed and the final structure is usually 
paucimannose or oligomannose which might be cleared quickly or immunogenic due 
to their absence in humans (Durocher and Butler, 2009). Whilst insect cells possess a 
core-fucosylation α1,6-fucosyltransferase, the presence of an α1,3-fucosyltransferase 
means they are able to add fucose to the glycoprotein with the immunogenic α1,3 
fucose linkage (Altmann et al., 1999). The sialic acid biosynthetic pathway and an 
active sialyltransferases do not exist in most insect cell lines and thus glycoproteins 
produced with these cell lines would result in reduced serum half-life (Marchal et al., 
2001). To date, there has not been any therapeutic protein that has been approved 
(Durocher and Butler, 2009).  
 
In order to move toward that possibility, the N-glycan processing pathways in insect 
cells have been re-engineered to produce more human-like glycosylation. The GnT II 
and galactosyltransferases were cloned into the insect cell to result in bi-antennary 
complex type glycan (Tomiya et al., 2002). Sialyltransferases which attach sialic acid 
in α2,6 and α2,3 linkages have been cloned into these cell lines together with the use 
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of sialic acid-rich medium to achieve sialylation of the N-glycan (Hollister et al., 
2002). Finally, a heterologous and functional sialic acid biosynthetic pathway which 
consists of UDP-GlcNAc 2-epimerase/ManNAc kinase, N-acetylneuraminate-9- 
phosphate synthase and CMP-sialic acid synthase has been successfully transferred 
into lepidopteron cells in functional forms (Viswanathan et al., 2003). More recently, 
a single Sf9 cell line was generated with five glycosyltransferases (GnT I, GnT II, 
β4GalT, ST3Gal and ST6Gal) and two enzymes of the CMP-sialic acid biosynthetic 
pathway (N- acetylneuraminate-9-phosphate synthase and CMP-sialic acid synthase) 
(Aumiller et al., 2012). It was observed that the cells expressed N-glycans with sialic 
acid residues on both α1,3- and α1,6- branches of N-glycans (Aumiller et al., 2012). 
 
2.3.4  Mammalian cells 
 
Unlike the aforementioned cell lines, mammalian cells are naturally capable of 
producing glycoproteins with complex and hybrid N-glycan structures. But the 
challenge in bioprocesses using these cell lines is managing the heterogeneity of the 
glycan structures that are present as well as eliminating certain non-human 
glycosylation epitopes which are immunogenic when used in human therapy.   
 
CHO 
Chinese hamster ovary (CHO) cells are by far the most commonly used mammalian 
cell lines with nearly 70% of all recombinant proteins produced with it (Wurm, 2004). 
Biologics produced using CHO cells have a value of more than US$30 billion 
worldwide. Over the years, the cell line has proven to be a safe host cell line for the 
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production of recombinant proteins for use in humans because the resultant glycan 
structures produced in these cells resemble human glycosylation to large extent and 
are thus compatible to the humans. However, glycans attached by CHO glycosylation 
machinery do differ to human glycosylation in some ways. For one, the glycans do 
not contain α2,6 linked sialic acid that may lead to undersialylation and reduced 
serum half-life (Fukuta et al., 2000b). They also do not contain bisecting GlcNAc 
which may result in reduced biological activity in the case of Mabs (Umana et al., 
1999). This is due to the absence of functional α2,6-sialyltransferase and N-
acetylglucosaminyltransferase III (GnT III) respectively. CHO cells also possess the 
cytidine 5’-monophosphate-N-acetylneuraminic acid hydroxylase gene which humans 
do not possess, resulting in the hydroxylated version of sialic acid, 
glycolylneuraminic acid (Neu5Gc) being synthesized and incorporated into the 
glycans. Furthermore, media culture containing animal products often contain 
Neu5Gc, which can also be incorporated into the glycosylated proteins. The impact of 
this foreign sugar epitope has not been reported widely probably because the levels of 
glycans containing Neu5Gc do not invoke a significant immunogenic response.  
 
Murine myeloma cells  
Murine myeloma cells such as NS0 and SP2/0 are mostly commonly employed in the 
production of therapeutic monoclonal antibodies. They are also capable of α2,6 
linked sialylation but also produce N-glycans containing the immunogenic alpha-gal 
epitope in sufficiently immunogenic levels. The immunogenicity of alpha-Gal was 
particularly evident in the anaphylaxis induced in patients who had been administered 




BHK-21 cells are less commonly used in biologics manufacturing although they are 
able to produce proteins with glycosylation that is very similar to CHO cells. It 
similarly expressed only α2,3 linked sialic acid terminated glycans and is able to 
produce Neu5Gc capped glycans. Human derived cell lines such as human embryonic 
kidney cells (HEK293) and human embryonic retinal cells (Per.C6) are increasingly 
being preferred due to the similarity of their glycosylation to their natural counterpart. 
Their application in biologics manufacturing is still limited. HEK293 is only used for 
the production of Xigris (Eli Lily) and PER.C6 is currently being used for the 
production of primarily vaccines that are glycoproteins in clinical trials.  
 
2.4  Strategies for improving sialylation in CHO cells  
 
As mentioned in point 1.2, because glycosylation has a huge impact on the efficacy of 
glycoprotein protein based therapeutics, much research has been done to study how 
sialylation can be improved.  
 
The overexpression of different glycosylation genes has been studied in a bid to 
improve the sialylation in various model proteins. The tumor necrosis factor receptor 
IgG1 fusion protein had been reported as under galactosylated and undersialylated. 
The overexpression of a human galactosyltransferase, β1,4-galactosyltransferase and 
human sialyltransferase, α2,3-sialyltransferase, in established cell lines producing 
TNFR-IgG1 resulted in an increase in galactosylation as well as sialylation. In the 
same report, an established cell line producing T103N, N117Q, KHRR(296–299)- 
AAAA–tissue plasminogen activator (TNK-tPA), which was producing variably 
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undersialylated glycoforms in fed-batch conditions, was transfected with expression 
plasmid containing human α2,3-sialyltransferase coding sequence. The 
overexpression of the sialyltransferases was again demonstrated to increase the 
sialylation as observed by MALDI-TOF mass spectrometry analysis of the purified 
glycoprotein (Weikert et al., 1999).  
The CMP-sialic acid biosynthetic pathway as well as the supply of CMP-sialic acid 
within the Golgi has also been the subject of some studies. Bork et al. (2007) 
investigated the possibility of overexpressing a UDP-N-acetyl- glucosamine 2-
epimerase/N-acetylmannosamine-kinase (GNE) that harbored a mutation that is 
contained in similar enzyme in patients suffering from sialuria. This mutation in the 
epimerase overrides the negative feedback loop, which prevents the enzyme from 
producing too much sialic acid. The overexpression of this mutant form of GNE in an 
established CHO cell line producing EPO was shown to improve the sialylation as 
analyzed by IEF.  
 
Wong et al. (2006) also overexpressed the CMP-sialic acid transporter in order to 
increase the amount of sialic acid available for the sialyltransferases in the Golgi. In 
this study, the IFN-γ producing CHO cell line was also shown to have improved 
sialylation as analyzed by total sialic acid quantification using the thiobarbituric acid 
assay.  
 
Jeong et al. (2009) stably expressed a combination of human α2,3 sialyltransferase  
and CMP-sialic acid transporter in EPO-expressing CHO cells and reportedly 
achieved a marginal increase in EPO sialylation. Another report by the same group 
used a combinatorial expression of sialuria-like mutated Rat GNE, Chinese hamster 
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CMP-sialic acid-transporter and human α2,3-sialyltransferase (Son et al., 2011). ` 
This study found that the EPO produced by the genetically engineered cell line 
expressed tetra-sialylated glycan which was higher by 32%. Concurrently, asialo and 
mono sialylated glycans decreased by 50% and the overall increase in sialic acid 
content was 43% compared to control cells.  
 
The work by Jeong et al., 2009 using α2,3-sialyltransferases was actually preceded by 
the work done by (Fukuta et al., 2000b) . In his study, Fukuta et al. overexpressed 
either α2,6- or α2,3- sialyltransferases into CHO cells producing recombinant IFN-γ 
with ectopically expressed GnT V which resulted in an increase in sialylation by 19%.  
 
There have been studies to improve the sialylation of glycoproteins by reducing or 
knocking down sialidases expressed in CHO cells. Sialidases are glycosidases which 
cleave the sialic acid from glycoproteins and glycolipids (Saito and Yu, 1995). Four 
sialidases (Neu1-4) have been characterized so far and they exist in different 
compartments of the cell. Neu1 and Neu4 have lysosomal sialidases whilst Neu2 is 
located in the cytosol. Neu3 is a plasma membrane protein. The Neu2 expressed in 
CHO cells was previously characterized (Burg and Müthing, 2001), whilst two 
separate reports show the sialic acid of recombinant glycoprotein could be increased 
through the reduction in CHO Neu2 by RNAi (Ferrari et al. 1998; Ngantung et al., 
2006). Ferrari et al. (1998) generated CHO stable cell lines with knocked down levels 
of Neu2 and expressed DNase as a model glycoprotein. The report observed 20–37% 
increase in sialic acid content. Ngantung et al. (2006) reportedly managed to maintain 
sialic acid profiles of recombinant through all phases of cell culture by knocking 
down the expression of the same Neu2 through stable expression of siRNA targeting 
 17 
the Neu2 gene. ( Zhang et al., 2010) identified two other sialidases in CHO, Neu1 and 
Neu3, and knocked down their expression using RNAi technology. In the knockdown 
of Neu3, the sialylation of recombinant human IFN-γ was improved at both live and 
death phases.  
 
Another report seems to refute the studies that the overexpression of certain 
glycosylation genes could help in the improvement of sialylation in CHO 
glycoprotein expression. A systematic study of the overexpression of 31 singly 
transfected single glycosylation genes was undertaken in a study for the improvement 
of EPO sialylation in CHO cells (Zhang et al., 2010). It was found in this study that 
the sialylation of transiently expressed EPO could not be improved through the 
overexpression of any of the glycosylation gene used in the study.  
 
2.5  N-acetylglucosaminyltransferase I (GnT I) and glycosylation mutants 
with defective GnT I 
 
N-acetylglucosaminyltransferase I, also known as UDP-GlcNAc:a-3-D-mannoside P-
1,2-N-acetylglucosaminyltransferase I, is an inverting glycosyltransferase that 
belongs to the SGC superfamily of transferases (Ünligil et al., 2000). It was first 
cloned by the complementation of phage lambda library in cells isolated from lectin 
screening using Phaseolus vulgaris (Kumar et al., 1990). The gene has been cloned in 
rabbits, mice, rats and humans. The coding sequence of the functional enzyme is 
contained in the second exon, which includes a stretch of 5’ UTR and the 3’ 
untranslated region(Yip et al., 1997.). 
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Based on sequence homology of this enzyme between C. elegans, rabbit and human 
and other species, it was determined that the alpha helix and loops in the predicted 
protein structure lasted till amino acid 105 and that 106 was the start of another beta 
sheet. The sequence homology was also highly similar from amino acid 106, 
suggesting that the catalytic domain might start from that amino acid. Indeed, it was 
found that by transfecting different lengths of cDNA into mutant cells that the 
absence of the first 29, 84 and 106 N-terminal amino acids did not affect the activity 
of GnT I. The study also showed that a further removal of another 14 amino acids 
resulted in a loss of GnT I activity (Sarkar et al., 1998).  
 
The crystal structure of the rabbit GnT I has been published. In that study, the putative 
catalytic fragment (amino acid 106-447) of GnT I purified from rabbit liver was 
crystallized in the presence of Mn2+ and UDP-GlcNAc. The crystal structure shows 
that the catalytic portion of the protein consists of two domains, the larger N-terminal 
domain of 8 beta sheets, β1-8, 6 alpha helices (α1−6) and a small two-stranded anti-
parallel b sheet (β4’ and β8’). The N-terminal domain also contained two disulfide 
linkages. The first linked the β1 sheet to the β2 sheet by connecting the C115 to C145. 
The second linkage joined β5 to β8 by connecting C239 to C305. The C-terminal 
domain (amino acids residues 354 to 447) contains 4 beta sheets (β9, β10, β13, β14) 
and 3 alpha helices α7-9 and a beta finger (β11 and β12). These two domains are 
linked via amino acid residues 331-353.  
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An important finding in the crystal structure of GnT I is the DxD motif that has been 
identified as the 211EDD213 (Ünligil et al., 2000). The DxD motif is a canonical motif 
that contains two aspartic residues in the sequence, hhhDxDxh. Further to the DxD 
motif in GnT I, the L214 forms residues I to I+3 connecting β4 to β4’ in a type I β 
turn. This motif is important as it has been shown to interact with the Mn2+ ion and 
make a hydrogen bond with the metal ion coordinated water molecules. In GnT I, the 
213D is the only molecule that makes direct contact with Mn2+ ion.   
 
GnT I is has physiological importance as can be seen from the embryonic lethality 
seen in GnT I null mice. Several GnT I mutants have been isolated either through 
mutagenesis and subsequent lectin selection (Reeves et al., 2002) or natural occurring 
mutants that have been isolated directly through lectin selection (Stanley and 
Siminovitch, 1977).  The first GnT I CHO mutants were isolated through lectin 
isolation using the lectin Phaseolus vulgaris (L-Pha) and were subsequently 
discovered to be GnT I mutants after gene complementation (Kumar et al., 1990). 
These were labeled as Lec1 cells. Subsequently, another set of GnT I mutants also 
selected in the same way, were characterized as containing mutations with partially 
functional GnT I and were labeled as Lec1A cells (Chen et al., 2001). More mutants 
were characterized, with more mutations in GnT I that lead to the loss of function of 
the enzyme were published (Chen, 2002). Mutant GnT I cells from baby hamster 
kidney cells have been isolated through the lectin selection using ricin (Opat et al., 
1998). A mutant human embryonic kidney cell line, 293S, has also been isolated 
through mutagenesis with ethyl methanesulfonate and selection with Ricin. It was 
subsequently used for the production of rhodopsin to show how mutant cell lines that 
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give simpler glycosylation structures can be used for producing protein for crystal 
structure studies (Reeves et al., 2002).   
 
Other CHO cell lines deficient in GnT I were isolated for the purpose of producing 
monoclonal antibodies (Mabs) that contain unfucosylated oligomannose glycan 
structures (Zhong et al., 2012). However the study also showed that the CHO cells 
could not be adapted to protein free suspension culture and thus was not suitable for 
industrial purposes. Most recently, the GnT I mutants were generated by using zinc-
finger nuclease technology to knock out the GnT I gene for the same purpose of 




Erythropoietin (EPO) is a glycoprotein hormone that regulates the maturation of red 
blood cells (Graber and Krantz, 1977). As a recombinant therapeutic drug, it is 
utilized to treat anaemic patients suffering from chronic kidney disease or cancer. 
EPO contains three N-glycans and one O-glycan (Lin et al., 1985). In the EPO 
produced by CHO cells, the glycans make up about 40% of the total mass of the 
molecule. High degree of sialylation of the N-glycans plays an important role in 
increasing the circulatory half-life of EPO in vivo (Takeuchi et al., 1989), resulting in 
higher efficacy of the drug. Increased branching of N-glycans on EPO has also been 
shown to improve the circulatory half-life of the glycoprotein (Egrie and Browne, 
2000; Misaizu et al., 1995). Therefore, glycosylation has a significant impact on 
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CHAPTER 3   MATERIALS AND METHODS 
 
3.1  Cell culture  
CHO-K1 cells were a gift from Dr. Donald K. MacCallum (University of Michigan 
Medicine School, Ann Arbor, MI, USA) and were cultured in Dulbecco’s modified 
eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS). 
Glycosylation mutant cells derived from the parental CHO-K1 cells were cultured in 
the same media.  Lec1 cells were kindly provided by Dr. Pamela Stanley (Albert 
Einstein College of Medicine, Yeshiva University, Bronx, NY, USA). These cells 
were cultured in α-Modified Eagle’s Medium supplemented with proline (40mg/L) 
and 10% FBS. DHFR deficient CHO-K1 glycosylation mutant cells were cultured in 
Iscove’s modified Dulbecco’s medium supplemented with 10% dialyzed FBS and 1x 
hypoxanthine and thymidine supplement (Life Technologies, USA). All cells were 
cultured in a cell culture incubator maintained at 37°C and 5% CO2. 
 
3.2  Isolation of RCA-I resistant clones 
 
Dr. Song Zhiwei in Massachusetts Institute of Technology (MIT) initiated the 
isolation of glycosylation mutants from CHO-K1 cells using RCA-I, with the help of 
Ms. Lim Sing Fee and Mr. Jonathan Wong. Subsequently, Mr. Chan Kah Fai isolated 
many more mutants when the project was continued in the Bioprocessing Technology 
Institute. Cells were seeded in six-well plates and allowed to adhere overnight in the 
presence of serum supplemented culture media. The cell culture supernatant was then 
aspirated and washed with 2 mL of phosphate buffered saline (PBS). Serum free 
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media containing 5, 10, 15 and 20 µg/mL of the lectin, Ricinus communis agglutinin 
(RCA-I) was then incubated with the cells overnight. This was then aspirated and 
replaced with culture media containing serum. Over the next two days, most cells 
were observed to have morphology consistent with apoptotic cells. These cells round 
up, float and no longer are attached to the culture plate. Cell culture media was 
refreshed every two days. After two weeks, colonies of CHO cells were observed to 
be growing and these colonies were picked.  
 
3.3 Expression constructs 
 
Open reading frame sequences for glycosylation genes and erythropoietin were 
cloned into pcDNA 3.1 (+) expression plasmids.  
The coding sequence for EPO, IRES and GnT I was joined via overlap PCR and 
cloned into the pcDNA 3.1(+) expression plasmid and was named pEIG.  
The pEGD vector was constructed for the tricistronic expression of EPO, GnT I and 
DHFR driven by a single CMV promoter. In the pEGD vector, the open reading 
frames of EPO, GnT I and DHFR are linked together by ECMV internal ribosome 
entry site (IRESwt) and an attenuated IRES (IRESatt). A modified pcDNA 3.1(+) 
vector, that was used to create the pEGD vector, was a gift from Dr. Yuansheng Yang 
(Ho et al., 2012). CHO-gmt4D cells were transfected with the pEGD vector using 
Lipofectamine 2000 (Life Technologies, USA).   
 
3.4  Transient expression of recombinant EPO in CHO cells 
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CHO cells were transfected with expression plasmids containing EPO coding 
sequence using Lipofectamine 2000 according to the vendor’s instructions. CHO cell 
supernatant was then collected 48 hours after transfection for further analysis.   
 
3.5  RNA extraction and cDNA synthesis 
 
Cells were trypsinized and resuspended in culture media and cells were counted using 
CEDEX automated cell counter. 1x107 cells were pelleted and washed with phosphate 
buffered saline and pelleted again. Total RNA was extracted from the cell pellet using 
RNAqueous kit Ambion, USA). Complementary DNA (cDNA) was synthesized 
using moloney murine leukemia virus reverse transcriptase (Promega, USA) with 2 
µg of total mRNA.   
 
3.6.1 Polymerase chain reaction to amplify wild-type and mutant GnT I coding 
sequence 
 
Forward and reverse primers specific for the Chinese hamster N-
acetylglucosaminyltransferase I were used to amplify the coding sequence by 
polymerase chain reaction with pfx platinum (Life Technologies, USA)  
Forward primer with HindIII restriction site and Kozak sequence (underlined): 
5’ GCGAAGCTTGCCACCATGCTGAAGAAGCAGTCTGCA 3’   
Reverse primer with Xho I restriction site: 
5’ GGCCTCGAGCTAATTCCAGCTAGGATCATAG 3’ 
Amplified cDNA was visualized on agarose gel electrophoresis and  extracted from 
agarose gel using QIAquick® Spin (Qiagen, USA). The expression vector pcDNA 3.1 
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(+) and GnT I cDNA was incubated with restriction enzymes HINDIII and Xho I and 
subsequently purified using QIAquick® Spin (Qiagen, USA). The resulting digested 
DNA were ligated using T4 ligase (New England Biolabs, USA) and transformed into 
DH5α chemically competent cells. Successfully transformed colonies were picked 
from cultured LB agar plates containing ampicillin (100µg/ml) and were analyzed 
using polymerase chain reaction with the same primers listed. Positive colonies were 
inoculated in 2 mL LB culture and the plasmid vectors were extracted using mini-prep 
kit (Promega, USA). 
 
3.7  Sequencing 
 
The wild-type and mutant GnT I cDNA was sequenced after being cloned into 
pcDNA3.1(+) constructs using BigDye 3.1 (ABI, USA). As the GnT I cDNA was 
about 1.4 kb, internal primers as listed below were synthesized such that the 
sequencing could cover the entire length of the open reading frame.   
Sequencing Primer 1: 5’ ATCCTGGTCATTGCCTGTGAC 
Sequencing primer 2: 5’ AGAACAGACCCCTCCCTTTGG 
Sequencing primer 3: 5’ TACTTGCAGCGGGAGGCTTAT 
Primers were used separately in cycle sequencing PCR reactions with the following 
components and PCR cycling information.  
    Volume (mL) 
Big Dye     1.0 
Buffer    1.0 
Primer (10 nM)  0.5 
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Plasmid DNA    250 ng  
Double distilled water  make up to 10 µL 
 
PCR cycle information 
Denature:   95°C 2 min 
Denature:   95°C 1 min 
Anneal:   45°C 2 min 
Extension:   95°C 2 min 
 
A minimum of 5 plasmid bearing bacterial colonies were sequenced for each mutant 
cell line that was being characterized.  
 
3.8  SDS-PAGE and western blotting  
 
Cell culture supernatant was incubated with 5x reducing dye at 95OC for five minutes 
before loading into 10 well 10% Bis-Tris SDS-PAGE gel (Life Technologies). SDS-
PAGE gel electrophoresis was performed at 100 V for 2 hours in a protein gel 
electrophoresis tank filled with NUPAGE MES buffer. Western transfer onto a PVDF 
membrane was performed at 100 V for 60 minutes with an ice pack in blotting buffer 
(10% v/v methanol, Tris-glycine).  The PVDF membrane was then incubated in 5% 
blotting powder dissolved in 1% Tween in phosphate buffered saline. Anti-EPO 
antibody was added at a concentration of 1:1000 and incubated with the membrane 
overnight at 4 OC. The membrane was washed with 1% Tween in phosphate buffered 
saline three times, before the secondary anti-mouse IgG antibody was added at a 
dilution of 1:10000 and incubated at room temperature for one hour.  
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3.9  Endonuclease H, neuraminidase and PNGase F treatment of cell 
supernatant samples 
 
50 µL of cell supernatant containing recombinant protein were treated with 3 µL 
endonuclease H, neuraminidase and PNGase F overnight at 37 OC. 
 
3.10  Isoelectric focusing and immunoblotting 
 
Isoelectric focusing gel was cast using an existing protocol previously published 
(Schriebl et al., 2007). The IEF gels used have a pH gradient of 3-10 and are cast 
using different immobiline solutions, according to the table below.  
 
Reagent Acidic Vol (µL) Basic Vol (µL) 
pKa <2.0 1066 - 
pKa 3.6 311 311 
pKa 4.6 282 282 
pKa 6.2 305 305 
pKa 7.0 228 228 
pKa 8.6 284 284 
pKa 9.3 321 321 
pKa 12.0 - 499 
  
Table 3.1 Casting of isoelectric focusing gel with pH gradient 3-10 
 
The cast gel is allowed to polymerize at 50 °C for two hours, after which it is 
removed from the glass plates and washed in water for 4x15 minutes and 1x15 
minutes in 1.5% (v/v) glycerol solution. The gel is then dried at 50 °C overnight and 
then kept till needed.  
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Before loading of the sample, the gel was reswelled in a solution containing urea 
(6M), dithiotreitol (0.01 M), CHAPS (2% (w/w)), bromophenol blue 0.1% (0.4% 
(w/w)) and Pharmalyte 3–10 (2% (w/w)).  
 
Gel loading cups were also impressed into the gel at the basic end of the gel such that 
the sample could be introduced into the gel easily. An overlay of paraffin oil was 
applied on top of the gel and wet filter paper was sandwiched between the electrodes 
and gel to facilitate conductivity.  
 
3.11  Expression and purification of EPO-Fc fusion protein 
 
EPO-Fc is a fusion protein that is made up of EPO linked to the Fc region of human 
IgG1. The coding sequence for this protein was constructed by overlap PCR. The Fc 
region also had been mutated such that the glycosylation site at Asn 297 was changed 
to Ala. To produce enough EPO-Fc for analyses, ten T-150 flasks of cells were 
transfected with the EPO-Fc expression using Lipofectamine 2000 (Life Technologies, 
USA). After transfection, the cell culture media was changed to protein free HyQ 
media and the cell culture supernatant was harvested 48 hours after.  
 
Cell culture supernatant was then desalted using a concentrator and buffer exchanged 
with 20mM sodium phosphate buffer (pH 7.2). Protein A chromatography column 
was equilibrated with phosphate buffer (pH 7.2) with five column volumes and then 
loaded with the sample.  The chromatography column was washed again with the 
loading buffer until the UV signal reached a stable baseline. An elution buffer of 0.1 
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M glycine (pH 3.2) was used to elute EPO-Fc that is bound to the column into 
collection tubes filled with neutralizing buffer (Amersham).   
 
3.12  High pH anion exchange chromatography pulsed amperometric detection 
(HPAEC-PAD) 
 
100 µg of purified protein samples were buffered at a pH of 8.2 with 50 mM 
ammonium bicarbonate after which, the samples were then incubated with 4 µg of 
trypsin for every 100 µg of protein at 37 °C  for 6 h. The mixture was then incubated 
at 80°C for 10 min to inactivate the trypsin and cooled to room temperature. 5 mM of 
PNGase F was then added to cleave the N-glycans from the protein and incubated 
overnight. The cleaved glycans were then purified using Hypercarb SPE cartridges 
(Thermoscientific, USA) according to manufacturer’s instructions and dried in a 
CentriVap benchtop vacuum concentrator (Labcon, USA). Samples were then 
reconstituted in 150 µL of water and analyzed using the BioLC system with integrated 
amperometry (Dionex Corporation). A PA100 analytical column (2 × 250 mm) was 
used for separation and samples were eluted with a combination of 500 mM CH3 
COONa, 500 mM NaOH, and water. The gradient program for the elution of both 
neutral and charged oligosaccharides began with an equilibration period of 25 min 
with 20% NaOH and 80% water, a start injection on isocratic mode for 10 min, 
followed by a ramp gradient for CH3COONa to reach 46% whilst maintaining NaOH 
at 20% until 75 min. The waveform used was E1 = +0.05 V, t1 = 400 ms; E2=+0.75V, 
t2 =200ms;E3=−0.15V, t3 =400ms. The flow rate was kept constant at 0.25 mL/min 
and the volume of sample/standard injected was 30 mL.  
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3.13  Total sialic acid quantification of EPO-Fc 
 
Total sialic acid quantification for EPO-Fc was performed using the thiobarbituric 
acid (TBA) assay. Duplicate samples, each containing 3.5 µg of purified EPO-Fc was 
incubated with neuraminidase overnight. 25 mL of periodic acid (25 mM dissolved in 
0.125 M hydrochloric acid) was added to the sample and incubated for 30 min at 
37 °C. 40 mL of sodium arsenite (2% in 0.5 M hydrochloric acid) was then added and 
incubated at room temperature until the yellow solution turned colourless. 0.4 mL of 
thiobarbituric acid (adjusted to pH 9.0) was added and incubated in a water bath at 
95°C for 8 min and then snap-cooled in an ice bath. 1.5 mL of 95% (v/v) butanol, 5% 
9v/v) HCl and 0.7% ml of water were added before the sample was centrifuged at 
13,000 rpm for 5 min. The upper aqueous solution was withdrawn from the mixture 
and its absorbance was measured at a wavelength of 549 nm. The readings were then 
compared with a standard curve using standards diluted between 1-5 nM of sialic acid 
(Sigma, USA).  
 
Total sialic acid quantification for purified EPO samples were performed using a 
more recent published assay (Markely et al., 2010). Briefly, without the addition of 
tetrabutylammonium borohydride, 30 µL of sample was adjusted to pH 5.2 with the 
addition of 30 µL acetate buffer (0.1 M, pH 5.0). Neuraminidase (Roche Diagnostics, 
Mannheim, Germany) was then added and incubated at 37 °C for 5 minutes. Sialic 
acid released was derivatized by the addition of 90 µL of borate buffer (0.15 M, pH 
9.4) and 12 µL of malononitrile (8 g/L) and incubated for 5 minutes at 80 °C before 




3.14  Construction of zinc-finger nuclease expression plasmid targeting 
dihydrofolate reductase 
 
The DNA recognition amino acid sequence that targeted dihydrofolate reductase was 
taken from previous published literature (Santiago et al., 2008). The amino acid 
sequence for the left and right fingers are listed below, together with the 
corresponding DNA coding sequence that was obtained by reverse translation using 





Finger 1:           RSDTLSE         aggtccgacaccctgtccgag  
Finger 2:           NNRDRTK         aacaacagggacaggaccaag 
Finger 3:           RSDHLSA         aggtccgaccacctgtccgcc 




Finger 1:           QSGALAR        cagtccggcgccctggccagg 
Finger 2:           RSDNLRE         aggtccgacaacctgagggag 
Finger 3:           QSSDLSR         cagtcctccgacctgtccagg 
Finger 4:           TSSNRKT         acctcctccaacaggaagacc 
 
The scaffold of the zinc finger was taken from another publication (Urnov et al., 2005) 
which is essentially based on the Zif268 architecture with space for four DNA 
recognition motifs. The nuclease that was joined to the zinc finger portion utilized the 
ELKK FOK I variants via overlap PCR. 
 
3.15 Sorting of zinc-finger nuclease transfected cells 
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Constructs that express the zinc finger nucleases (ZFN) to target the DHFR gene were 
transfected in CHO-gmt4 (JW152) cells using Lipofectamine 2000 (Life 
Technologies, USA) according to manufacturer’s instructions. Transfected cells were 
sub-cultured 48 hours later into T25 flasks and cultured for another 48 hours. Cells 
were then incubated with 3 µM fluorescein-methotrexate (Life Technologies, USA) 
and sorted using the FACSAria (Becton-Dickinson, USA). Negatively stained cells 
were pooled and cultured for a week. Cells were sorted again and negatively stained 
cells were collected for single cell cloning. Single clones that failed to bind to 
fluorescein-methotrexate were expanded for genomic DNA extraction using Puregene 
(QIAGEN, USA). The targeted DHFR locus was amplified by PCR and sequenced. 
 
3.16 Genomic extraction and PCR amplification  
 
Single clones that failed to bind to fluorescein-methotrexate (Life Technologies, USA, 
catalog no. M1198MP) were expanded for genomic DNA extraction using Puregene 
(QIAGEN, USA). The genomic DNA served as template for PCR reaction using pfx 
polymerase (Life Technologies, USA) with the following primers which are 
positioned within the genomic DNA sequence listed below, highlighted in blue. The 
zinc-finger nuclease cut site is highlighted in red.  
 
Forward primer 
5’  CTCCGATTCACAAGTGGGAAG 
Reverse primer 
3’ TCCATCTCAGCGGCTACCGATGCA 
>gi|191060|gb|M13129.1|CRUDHRA Chinese hamster dihydrofolate 


























The sequence highlighted in red is the target site for the zinc-finger nuclease.  
 
Highlighted in blue are the primers that flank the zinc-finger nuclease target site  
3.17  Western blot of cell lysate to confirm the absence of DHFR  
 
2 million cells from CHO-gmt4 parental cell line, CHO-gmt4D and DG44 cells were 
lysed in 200 uL of lysis buffer. 40 uL was used for western blot analysis using an 
antibody specific for CHO-DHFR protein from Santa Cruz Biotechnology, USA 
(catalog no. sc-14780). 
 
3.17 Transfection, selection and amplification of stably transfected cells with 
pEGD 
 
CHO-gmt4D cells transfected with pEGD were sub-cultured 24 hours after 
transfection and the culture medium was replaced with selection medium which 
consists of IMDM supplemented with 10% dialyzed FBS. When a stably transfected 
pool was obtained, single clones were picked and analyzed by dot blot analyses for 
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EPO expression. The sialylation patterns of the recombinant EPO from these clones 
were analyzed by isoelectric focusing (IEF) followed by Western blot (S. F. Lim et al., 
2008). Clones with enhanced productivity and sialylation patterns were then amplified 
with 50 nM MTX.  After amplification, single clones with higher productivity and 
more superior sialylation patterns were further amplified with 250 nM MTX before a 
final round of single clone selection.   
 
3.19  Coomassie blue staining of IEF gel 
 
The sialylation patterns of recombinant EPO in different samples were analyzed by 
IEF followed by Western blot as previously described (Lim et al., 2008). IEF gels 
were first fixed in a solution that contains 11.5 % (w/v) tetrachloroacetic acid and 
3.5% (w/v) 5-sulfosalicylic acid in water. The gels were then stabilized in a solution 
containing 0.5% SDS, 25% ethanol and 5% acetic acid in water. The IEF gels were 
then stained using 0.1% (w/v) Coomassie blue G-250 (BioRad, USA) dissolved in the 
destaining solution with 0.1% (w/v) copper sulphate. The gels were then destained in 
the destaining solution (25% ethanol and 5% acetic acid in water).   
 
3.20 Perfusion culture of CHO-gmt4D-GnT I EPO cells 
 
The perfusion culture was carried out in the bioreactor facility of Shandong E-Hua 
Biopharmaceutical Corporation, Ltd., following the standard operation procedures of 
that facility by Mr. Liu Yingwei under the supervision of Prof. Zhang Yuanxing. The 
culture was conducted in a 5-L CelliGen bioreactor (New Brunswick Scientific, 
Edison, NJ), which was equipped with Fibra-Cel® Disks to support cell attachment. 
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The dissolved oxygen concentration was controlled at 60% air saturation, and culture 
pH was kept at 7.0±0.05 by addition of NaOH or CO2 gas. Culture temperature was 
controlled at 37±0.1 °C. The perfusion rate was adjusted to maintain the glucose 
concentration in the culture medium at 0.5-1.0 g/L throughout the perfusion process. 
The perfusion culture was divided into two phases, the growth phase and the 
production phase. In the growth phase, exponentially growing cells in 8 roller bottles 
were collected and inoculated at about 1×106 cells/mL into the bioreactor with a 
working volume of 3.5 L and allowed to attach to the Fibra-Cel® Disks. The cells 
were cultured in perfusion mode in DMEM/F12 with FBS and the concentration of 
serum was gradually reduced from 10%, 8% to 6.5% before the medium was changed 
to serum-free medium. In the production phase, the culture system was washed twice 
with PBS to remove the serum content. Subsequently, CHO-S-SFM II (Life 
Technologies, USA) with 0.5 mM sodium butyrate was used to maintain the EPO 
production. The perfusion rate was adjusted according to the glucose uptake rate in 
the bioreactor. The agitation speed of the impeller was maintained at 120 rpm. 
 
3.21  Purification of EPO from perfusion culture 
 
The purification of EPO from the perfusion harvest was carried out in the facilities of 
the Shandong E-Hua Biopharmaceutical Corporation, Ltd., following their standard 
operation procedure of. Every 20 L harvest was filtered with 0.45 µm membranes to 
remove the cell debris, and then the culture supernatant containing EPO was loaded 
onto a column packed with CM Affi-Gel Blue gel (Bio-Rad, USA) which captures 
most of the proteins including EPO. Most of the pigments, nucleic acids and some 
proteins do not bind to the column, and are removed in this step. The EPO bound to 
 36 
the column was eluted and desalted with a Sephadex G-25 column (Amersham 
Pharmacia Biotech, Sweden) before being loaded onto a DEAE Sepharose column 
(Bio-Rad, USA) to remove most of the other proteins. As the process was not 
optimized for the purification of EPO in the supernatant obtained from the CHO-
gmt4D-GnT I culture, the EPO purified after the first DEAE Sepharose 
chromatographic step was not as pure as the EPO purified from the biosimilar line 
cultured at the same stage.  Thus, a C4 reverse phase column (Amersham Pharmacia 
Biotech, Sweden) and a Q-Sephadex column (Bio-Rad, USA) were used to further 
remove the miscellaneous proteins without losing EPO.  To purify the highly 
sialylated isoforms of EPO and remove the lesser sialylated isoforms, samples were 
further purified by another DEAE Sepharose column. 
  
3.22  Total sialic quantification of purified EPO samples 
 
Sialic acid quantification of purified EPO samples was carried out according to a 
previously published method (Markely et al., 2010) with slight modifications. Briefly, 
without the addition of tetrabutylammonium borohydride, 30 µL of sample was 
adjusted to pH 5.2 with the addition of 30 µL acetate buffer (0.1 M, pH 5.0). 
Neuraminidase (Roche Diagnostics, Mannheim, Germany) was then added and 
incubated at 37 °C for 5 minutes. Sialic acid released was derivatized by the addition 
of 90 µL of borate buffer (0.15 M, pH 9.4) and 12 µL of malononitrile (8 g/L) and 
incubated for 5 minutes at 80 °C .The reaction was quenched before the fluorescence 
was measured. The concentration of sialic acid was then calculated as described 
(Markely et al., 2010).    
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3.23 Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
mass spectrometry  
 
EPO samples were analyzed by using MALDI-TOF MS to further describe the N-
glycan structural information and distribution with reference to a previously published 
protocol (Morelle and Michalski, 2007). 200 µg of purified of EPO or EPO-Fc was 
incubated with 8 µg of sequencing grade modified trypsin (Promega, Madison, WI) at 
37 ◦ C in a 50 mM ammonium bicarbonate buffer (Merck) at pH 8.2 for 4 h. The 
digestion was stopped by heating at 95 ◦ C for 15 min. The resulting peptide mixture 
was then incubated with 70 U of PNGase F (Prozyme, Hayward, CA) at 37 ◦ C 
overnight to release the N-glycans. O-glycans were also released from the peptide 
mixture by reductive elimination method.  The released glycans were then purified 
using the Hypersep Hypercarb cartridges (Thermo Scientific), permethylated 
(Ciucanu and Kerek, 1984; Dell et al., 1993) and purified using a Sep-Pack C18 
cartridge (Waters Corporation, Milford, MA) (North et al., 2010). Permethylated 
samples were reconstituted in 30 µL of 80% (v/v) methanol in water and then spotted 
on a target plate on a ratio 1:1 with 2,5- dihydroxybenzoic acid matrix at 10mg/mL 
(Water Corporation) dissolved in 80% (v/v) methanol in water. The 4700 calibration 
standard kit, calmix (AB Sciex) was used as an external calibrant for the MS mode. 
The laser intensity used to acquire the data was 50%. The MALDI-TOF data was 
acquired on a 5800 MALDI-TOF/TOF mass spectrometer (AB Sciex, Foster City, CA) 
in positive reflectron mode. N-glycan structures were then assigned based on their 
mass-to-charge ratio (m/z), with the assistance of GlycoWorkBench software.  
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CHAPTER 4  CHARACTERIZATION OF CHO GLYCOSYLATION 





The isolation of glycosylation mutants has enabled the study of the glycosylation 
machinery of the mammalian system. These glycosylation mutants often produce 
glycoproteins bearing carbohydrate structures that are different and may have some 
utility in the study of the structure and function of different glycosylation enzymes or 
might produce recombinant glycoproteins with a specific carbohydrate structure for 
further study. 
 
This chapter deals with the isolation and characterization of a series of glycosylation 
mutants by using the lectin, RCA-I. RCA-I is a cytotoxic lectin which is endocytosed 
by the cell upon binding to the extracellular membrane protein and interferes with the 
intracellular trafficking of vesicles. RCA-I has been reported to be specific for 
galactose sugar residues and the initial impetus was to isolate glycosylation mutants 
that might be deficient in glycosylation genes such as galactosyltransferases, or the 
transporter of UDP-galactose or any other glycosylation gene that might lead to the 
unavailability of galactose.  
 
The isolation of glycosylation mutants using lectins as a genetic screen was first done 
by Pamela Stanley. Lectins are sugar specific protein molecules that are often found 
in plants and also mammalian cells that often play a role in innate immunity and 
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signaling. Some lectins are particularly cytotoxic and serve as a genetic screen for 
isolating cells having a natural resistance to these lectins owing to a genetic defect in 
their glycosylation gene. Lec1 is a CHO cell line that was isolated in one step by 
using Phaseolus vulgaris (L-Pha) and upon genetic complementation using human 
cDNA library, it was found to be deficient in the N-acetylglucosaminyltransferase I  
(GnT I) gene.  
 
Several CHO clones that were resistant to RCA-I were found to produce 
erythropoietin at a lower molecular weight. Using a genetic complementation system 
of co-transfecting various glycosylation genes with EPO expression plasmids and 
then analysis with IEF, it was found that all the RCA-I-resistant clones isolated were 
deficient in GnT I. The restoration of GnT I function was able to correct the 
incomplete sialylation of EPO as analyzed by IEF.  
 
These clones were subsequently further characterized to discover the specific genetic 
mutations that occur in the GnT I gene that led to the gene deficiency. Fourteen 
clones were characterized which led to the finding of ten unique clones with various 
genetic mutations that lead to a greater understanding of the GnT I gene.  
 
4.2  Results  
 
4.2.1  Lectin kill curve for CHO-wild type cells 
 
The cytotoxic lectin RCA-I has a high affinity to saccharide structures with galactose 
epitopes. In order to distinguish CHO glycosylation mutants from wild-type CHO 
cells, a kill curve was performed by subjecting CHO cells to limiting dilutions of 
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RCA-I. The concentrations used were 20 µg/mL, 15 µg/mL, 10 µg/mL, 5 µg/mL, 2.5 
µg/mL, 1 µg/mL and 0.5 µg/mL. At concentrations of 3 µg/mL and above, all of the 
CHO wild-type cells were observed to die (see Fig. 4.1). 
 
4.2.2 Isolation of RCA-I CHO clones 
 
CHO cells were cultured in 6 well plates at 80% confluence before cell culture media 
was aspirated and rinsed with phosphate buffered saline before serum free culture 
media was introduced. CHO cells were treated with different concentration of RCA-I, 
20 µg/mL, 15 µg/mL, 10 µg/mL and 5 µg/mL. After overnight incubation with RCA-I 
containing media was aspirated and cells were rinsed again with phosphate buffered 
saline before normal culture media was reintroduced. 
20 15 10 5
1 2 3 4
0.5 0.25 0.13 0
 
Figure 4.1 RCA-I kill curve on CHO-K1 cells.   
Cells were treated with various concentrations of RCA-I lectin in serum free media 
overnight and replaced with normal culture media. Culture wells with a minimum of 3 
µg/mL did not contain any live cells.  
  
Cells were observed to become rounded and become detached after a day in culture 
after treatment. The media was then refreshed every two days until single clones 
emerged. These colonies were then picked and cultured separately and banked.   
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4.2.3  SDS-PAGE analysis of transiently expressed EPO in JW152 
 
One of the cell lines, JW152, which was isolated from the lectin treatment, was 
characterized initially. The cell line was transfected with an expression plasmid 
containing the open reading frame of EPO. 48 hours post transfection, the supernatant 
of the cells was collected and analyzed by SDS PAGE and western blotting.  
Fig. 4.2 shows the western blot of supernatant from both CHO-K1 and JW152 cells 
that transiently express EPO. The protein band observed in lane 1 has an apparent 
molecular weight of 26 to 37 kDa. The protein band detected in the lane containing 
supernatant from JW152 cells has an apparent molecular weight of about 25 kDa.  
 
Supernatant samples were treated with endoglycosidase H (Endo-H) overnight and 
similarly analyzed using western blot and are contained in corresponding lanes 3 and 
4. The molecular weight of the EPO band in lane 3 is largely unaffected by the 
treatment with endo-H, however, EPO produced by JW152 appears to have a lower 
molecular weight after treatment with endo-H, indicating that it is sensitive to endo-H. 
Endo-H is an endoglycosidase that cleaves specifically high mannose glycan 
structures at the first GlcNAc sugar of the chitobiose core. This indicates that the 
glycan structure found on EPO expressed in JW152 cells do not contain hybrid or 
complex N-glycan structure but rather, high mannose structures.  
 
4.2.4  Complementation of EPO expression with co-transfection of glycosylation 
genes in JW152 
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Isoelectric focusing involves the separation proteins according to their isoelectric 
point. EPO being differentially sialylated, separates into multiple bands when 
analysed by IEF. The EPO bands have been separated by isoforms according to the 
pH gradient contained in the isoelectric focusing gel. The IEF gel has a basic pH 
which decreases from the bottom of the gel to the top where acidic pH is found. 
Samples are loaded at the bottom of the gel, at the basic pH region and a positive 
potential difference is applied at the acidic end, causing the EPO molecules that are 
better sialylated to migrate towards the acidic region. Thus, poorer sialylated EPO 







Figure 4.2 Recombinant EPO expressed in JW152 cells is sensitive to 
endoglycosidase H (Endo H) due to a genetic defect in GnT I gene.  
Western blot of recombinant EPO produced in CHO K-1 cells and in JW152 cells as 
indicated. Endo H-treated EPO produced in CHO-K1 and Endo H-treated EPO 
produced in JW152, as indicated.  
 
Fig. 4.3 displays the IEF of supernatant containing EPO expressed in CHO-K1 wild-
type cells, and in JW152 cells, and EPO expressed in JW152 when co-transfected 
with different glycosylation genes. These genes express glycosyltransferases and 
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glycosidases found in the initial part of the glycosylation pathway. They are α-
glucosidase I and α-glucosidase II (Gluase II), α-mannosidase IA, IB and IC (Manase 
IA, Manase IB, Manase IC), N-acetylglucosamine transferase I (GnT I), α-
mannosidase II (Manase II) and N-acetylglucosaminyltransferase II (GnT II). In the 
second lane of Fig. 4.3, the EPO bands are concentrated in the lower half of the blot 
and the bands in the upper half of the blot are not present as compared to the wild-
type CHO cell expressed EPO. Subsequent co-transfection with different 
glycosylation genes do not change the pattern observed on the IEF/western blot. Only 
with the transfection of GnT I is the IEF pattern changed such that the EPO bands are 
now seen in the upper half of the IEF/western blot. This leads to the indication that 




Figure 4.3 Isoelectric focusing of EPO samples in JW152 with co-expression of 
different glycosylation genes.  
The lane on the far left (CHO-K1) shows the EPO expressed in wild type CHO-K1 
cells as a control. The second lane shows the EPO produced in JW152 cells. For 
complementation test, several glycosylation related genes were separately co-
transfected with the EPO construct into JW152 cells. These genes include α-
glucosidase I (Gluase I), α-glucosidase II (Gluase II), α-mannosidase IA (Manase 
IA), α-mannosidase IB (Manase IB), α-mannosidase IC (Manase IC), N-
acetylglucosaminyltransferase I (GnT I), Golgi α-mannosidase II (Manase II) and N-
acetylglucosaminyltransferase II (GnT II). Only GnT I was able to complement the 
genetic defect in JW152 cells, suggesting that these cells lack functional GnT I gene. 
In the presence of GnT I, JW152 cells sialylate recombinant EPO better than the wild 
type CHO-K1 cells. 
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The expression of EPO in several other cell lines isolated via RCA-I selection also 
yielded similar EPO IEF/western blot patterns as seen in Fig. 4.4. In that figure, the 
first lane shows the IEF pattern from the clinical standard from Amgen that contains 
only highly sialylated EPO. Subsequent lanes show IEF patterns of EPO expressed in 
JW36, JW80, KFC-8, KFC-26, KFC-2, KFC-47, KFC-71, KFC-11 and CHO-K1. All 
mutant cell lines express EPO that separates into bands in the lower half of the 
IEF/western blot. This indicates that EPO expressed in the mutant cell lines contain 
inadequate sialylation.  
 
 
Figure 4.4 IEF analyses of EPO expressed in nine different RCA-I-resistant lines.  
Incomplete sialylation of EPO expressed is observed in all nine RCA-I-resistant 
mutants compared to EPO standard (EPO St.) on the far left lane and the EPO 




Figure 4.5 GnT I restored the glycosylation pathway in all nine RCA-I-resistant 
mutants. 
Fig. 4.5 shows the EPO transiently expressed in glycosylation mutant lines when GnT 
I is co-transfected with the EPO expression plasmid. The blots show that the EPO 
sialylation has been restored, indicating that GnT I is the defective gene in all the 
mutants that have been isolated by RCA-I and analyzed via EPO IEF/ western blot 
analysis.  
 
4.2.5  Cloning and sequencing of GnT I open reading frame in glycosylation 
mutants  
 
A total of 16 glycosylation mutant clones that were isolated from lectin selection were 
characterized. Total RNA was extracted from each glycosylation mutant cell line and 
first strand synthesis was then carried out using the derived RNA. The product from 
first strand synthesis was then used as template for PCR reaction using primers 
specific for GnT I open reading frames. For every cell line, a single PCR band was 
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observed. This indicated that the mutations in the GnT I coding sequence did not 
affect the stability of the transcribed mRNA stability.  
 
The PCR band was subsequently extracted, purified and cloned into a pcDNA 3.1 (+) 
expression plasmid. After bacterial transformation of the ligated product, a minimum 
of five bacterial colonies were cultured and plasmids extracted for sequencing to 
ascertain the genetic mutation that led to the loss in GnT I function in these 
glycosylation mutant cell lines. The chromatograms displayed below illustrate the 
resulting pairs of sequencing data for the mutant (top) and the wild-type CHO-K1 

























Figure 4.6 Chromatograms of sequencing results showing the mutation present 
in the respective mutant cell lines.  
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Mutant line Mutation Original amino acid Mutated to  
KFC -26 G246A Trp 82  STOP 
KFC-11 G258A Trp 86 STOP 
KFC-47 A859T Lys 287 STOP 
JW152  C1015T Gln 339 STOP 
JW36 A638C Asp 213 Ala 
KFC-2 C784G Arg 262  Gly 
KFC-71 T811A Trp 271 Arg 
JW80 G1300C Ala 434 Pro 
KFC-8 _706C  - Frame shift from amino acid 
236, STOP at 245 aa  
Table 4.1 Summary of mutations in the GnT I coding sequence found in 
glycosylation mutants isolated from RCA-I selection.  
 
Table 4.1 summarizes the mutations found from sequencing of the GnT I open 
reading frame of nine glycosylation mutants. Four glycosylation mutants contained 
stop codon mutations. The GnT I coding sequence in KFC-26 had a G246A mutation 
resulting in a stop codon mutation after amino acid 81. This is the largest deletion of 
365 amino acids being truncated from the C-terminus. KFC-11 had a G258A mutation, 
which lead to the tryptophan amino acid being mutated to a stop codon, 361 amino 
acids from the C-terminus. KFC-47 contained a stop codon mutation from lysine, 
resulting in 160 amino acids missing from the protein sequence due to the A859T 
mutation. JW152 had 108 amino acids missing arising from a stop codon mutation 
from glutamine. KFC-8 contained an insertion mutation; an extra cytosine is inserted 
in a stretch of 4 cytosine residues, which resulted in a frame shift and a premature 
stop codon mutation after 244. This is the same mutation that occurred in Lec1 cells 
(Chen and Stanley, 2002), and since these two cell lines were isolated from different 
parental cell lines and different lectins, it suggests that this particular base pair could 
be a mutational hotspot. Lec1 cells, whilst harboring the same mutation, are different 
from KFC-8 since the latter is a proline auxotroph. 
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Another four cell lines contain point mutations in the coding sequence. JW36 
contained an A638C mutation in the coding sequence GnT I, resulting in an amino 
acid substitution Asp213Ala. KFC-2 had a C784G mutation in the coding sequence 
resulting in an amino acid substitution Arg262Gly; KFC-71 had an amino acid 
substitution from Trp to Arg; and finally, JW80 had an amino acid substitution from 
alanine to proline.  
 
JW152 cells were transfected with EPO and expression plasmids containing the 
mutant GnT I which contained point mutations. These were the mutant GnT I coding 
sequences found in JW36, KFC-2, KFC-71 and JW80 cell lines. This was done to 
ascertain whether the point mutations rendered the GnT I completely inactive. From 
the IEF in Fig. 4.7, the sialylation pattern of EPO with the co-expression of GnT I 
found in JW36, KFC-2 and KFC-71 were similar to the EPO sialylation found in 
JW152, which has a stop codon. Interestingly, the sialylation pattern of EPO co-
expressed with GnT I found in JW80 had faint bands in the upper half of the IEF blot. 
This suggests that the mutant GnT I as encoded in JW80 could still be partially 
inactive. This was also observed in Fig. 4.4 where the transient expression of EPO in 




Figure 4.7 IEF analysis of EPO co-expressed with mutant GnT I coding sequence 
in JW152 cells.   
The overexpression of the mutant GnT I in JW152 shows that the point mutations in 
JW36, KFC-2 and KFC-71 do not result in complete sialylation. The over-expression 
of JW80 mutation GnT I results in faint bands at the top of the IEF gel.   
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Figure 4.8 Mass-spectrometry glycan analyses of glycans cleaved from EPO-Fc 
expressed in CHO-K1 and JW152 cells.  
CHO-K1 expressed EPO-Fc contains a variety of complex N-glycans whereas the 
major species observed for JW152 expressed EPO-Fc, which contained either 
fucosylated or non-fucosylated five-mannose structures.  
 
4.2.6  CHO-K1 and JW152 EPO-Fc glycan mass spectrometry analyses  
 
Large scale transfection of CHO-K1 and JW152 cells in ten T175 flasks for each cell 
line was performed and cells were subsequently cultured in serum free media to 
facilitate subsequent purification with protein A affinity chromatography. The cell 
supernatant was collected 48 hours after transfection and the EPO-Fc was purified 
and treated with PNGase F to cleave the N-glycans from the protein backbone. N-
glycans were then purified and prepared for MALDI-TOF. The results are shown in 
Fig. 4.8 where the glycans of EPO-Fc expressed in wild-type CHO-K1 cells contain 
varied complex-type N-glycan structures which are mostly fucosylated. JW152 cells 
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express EPO-Fc containing fewer N-glycan species and the major species are  five-
mannose structures with and without core-fucosylation. 
 
4.3  Discussion 
 
The GnT I mutants were isolated using RCA-I lectin although it was initially expected 
that other glycosylation mutants might arise from this lectin selection. RCA-I lectin is 
a plant lectin isolated from castor beans and consists of a heterodimer that is 
reportedly to have a high affinity to galactose (Baenziger and Fiete, 1979; Green et al., 
1987). Thus the mutants that may arise from this selection would include CHO cells, 
which express glycans terminating in GlcNAc as well as mannose. Interestingly, out 
of all the 21 cell lines characterized it was found that all were GnT I mutants. This 
suggests that RCA-I is capable of binding to many other glycan forms other than 
galactose, as reported in some reports (Iskratsch et al., 2009). This study reported that 
RCA-I is one of the less specific lectins and has been found to bind to several N-
glycan structures but with the least affinity towards Man3GlcNAc2, although 
Man5GlcNAc2 was not tested. RCA-I has also been found to bind with high affinity to 
lactosamine, notwithstanding the presence of the β-galactose being capped with α2,6 
sialic acid. This affinity is not present when β-galactose is capped with α2,3 sialic 
acid. RCA-I has also been suggested to bind to N-acetylglucosamine (Iskratsch et al., 
2009).  
 
This interesting property of RCA-I, to only isolate GnT I mutants, has been further 
validated in another study (Sealover et al., 2013). In this study, CHO cells had been 
transfected with zinc-finger nucleases targeting GnT I, after which the transfected 
cells were treated with RCA-I to enrich the cell population in cells that have been 
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successfully gene-edited by the zinc finger nuclease. The reports demonstrated a 35% 
increase in cells that were successfully gene-edited. The study also reported that in all 
the mutant cell lines, only one allele of GnT I has been found to be mutated leading to 
a total loss in GnT I function. This concurs in the findings of all our GnT I mutants 
found by RCA-I selection. It has been previously reported that CHO cells only 
contain one copy of the gene. Furthermore, southern blot analysis of human cells by 
using a probe targeting human GnT I was also observed to display one band, 
suggesting that GnT I gene exists as a single allele.  
 
GnT I mutants isolated from different lectins have been mentioned in literature, and 
the mutations that lessen or inactivate the function of this enzyme have been noted. 
These naturally occurring mutations, together with an existent crystallographic model 
of rabbit GnT I, shed light on the structure and function of this enzyme. The rabbit 
and hamster GnT I share 94% homology. A group of CHO mutants isolated from the 
CHO Pro- parental cell line through lectin selection using L-PHA was characterized. 
Only one functional allele was found in the parental cell line and 2 different point 
mutations from 2 different cell lines were found. They were Lec 1A.2C containing a 
A634G point mutation which resulted in a D212N amino acid substitution and Lec 
1A.5J which contained a C907T which resulted in an amino acid substitution, R303Y 
(Chen et al., 2001). The DXD motif is a specially conserved protein motif in 
glycosyltransferases and is found in the 212 and 213 amino acid residues. 
Surprisingly, the study on Lec1A.2C shows that the mutant GnT I is still functional 
albeit with lesser activity whereas the mutation found in JW36 which has the amino 
acid substitution D213A had been found, in this study, to be totally inactive as 
evidenced by the IEF.  
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In analyzing the genetic deficiencies and the resulting glycan structures of 
glycosylation mutants, fluorescent conjugated lectins have often been used to 
compare the FACs profile of mutants before and after restoration of the genetic defect 
(Chen et al., 2001). Another way would be to measure the sensitivity of a 
glycosylation mutant to the titrated amounts of various lectins(Patnaik and Stanley, 
2006). A recent paper utilized a mass spectrometry approach to identify the glycan 
structures present on the series of Lec cells (North et al., 2010). Another way of 
analyzing the resultant glycan structure would involve lectin precipitation of proteins 
from cell lysate (Lim et al., 2010) or the purification of recombinant proteins followed 
by mass spectrometry.  
 
The IEF/Western blot assay offers a simple and sensitive assessment on the extent of 
sialylation on recombinant EPO expressed in different glycosylation mutants. The IEF 
assay does not require the purification of the recombinant proteins thus allaying fears 
whether the method of purification actually loses certain glycoforms. Most defects in 
genes involved in the N-glycosylation pathway will affect the sialylation profile with 
the exception of enzymes involved in fucosylation (i.e. fucosyltransferase or GDP-
fucose transporter). This method has been proven to be fairly sensitive using a series 
of CMP- sialic acid transporter mutants (Lim et al., 2010). The difference in 
sialylation shown by IEF was confirmed by the HPAEC-PAD analysis. In fact, IEF is 
well-received as a method to compare the degree of sialylation of EPO. For example, 
the degree of sialylation of several recombinant EPO drugs on the market has been 
compared by IEF (Park et al., 2009). The World Anti-Doping Agency (WADA) relies 
on IEF patterns to detect the presence of recombinant EPO in human urine. The 
evidence is based on the difference in sialylation patterns analyzed by IEF (Lasne and 
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de Ceaurriz, 2000; Lasne et al., 2007). Disruption in these genes lead to truncated 
sialylation profile of EPO, with no bands observed in the acidic region of the IEF gel 
which means that sialylation was not possible due to the dysfunction of 
glycosyltransferases responsible for preceding sugars. Even with the absence of 
sialylated N-glycans in the case of PNGase F treated samples, there are still different 
isoforms being observed on the gel, which could be attributed to the presence of 
sialylated O-glycans and different occupational sites leading to different isoelectric 
point values of EPO.  It might be interesting to extract each band of a purified sample 
IEF analysis for mass spectrometry analysis.  
  
The glycosylation mutant JW152 was shown to produce EPO-Fc which contains the 
glycan structures Man5GlcNAc2(Fuc), Man5GlcNAc2, Man4GlcNAc2(Fuc), 
Man4GlcNAc2 as analyzed by MALDI-TOF. This makes the cell line highly suitable 
for the production of proteins that might be targeted towards therapy facilitated by 
cells which uptake these drugs through mannose-receptors. Thus the cell line could 
potentially be suitable for the production of recombinant glucocerebrosidase 
(Cerezyme manufactured by Genzyme) to treat Gaucher’s disease (Grabowski et al., 
1995; Van Patten et al., 2006). Cerezyme is recombinant glucocerebrosidase produced 
by wild type CHO cells and treated with sequential glycosidases until the mannose 
residue of the core structure (Man3GlcNAc2) is exposed. The terminal mannose 
residues of the N-glycans greatly enhance the internalization of the protein into the 
macrophages through its surface mannose receptors (Grabowski et al., 1995; Van 
Patten et al., 2006). Recombinant glucocerebrosidase produced in JW152 cells will 
eliminate the need for carbohydrate remodeling by sequential digestions using 
glycosidases (Grabowski et al., 1995).  
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Whilst glycans on EPO-Fc produced in the glycosylation mutant cell line have been 
shown to contain core-fucosylation, the glycosylation found in antibodies produced in 
similarly GnT I deficient cell lines contain no core-fucosylation (Sealover et al., 2013; 
Zhong et al., 2012) and demonstrate higher ADCC of such mutant cell line expressed 
antibodies. However the GnT I-deficient CHO-DUKX cells had been derived through 
the use of the mutagen ethyl methanesulfonate and selected using L-PHA and were 
found to grow poorly in protein free suspension culture. The zinc-finger nuclease 
gene edited CHO cells that were GnT I deficient were capable of producing the 
antibodies in a protein free suspension culture but the ZFN technology has already 
been patented and may not be a profitable route for commercialization. Furthermore, 
the isolation of GnT I mutants after gene editing is more efficient with the RCA-I 
enrichment step as mentioned in the study.   
 
A key parameter that is monitored for the production of therapeutic glycoproteins is 
the uniformity of glycosylation. Due to the heterogeneity of CHO glycosylation, it is 
often difficult to maintain this uniformity between batches. A smaller range in 
heterogeneity would therefore be more ideal for the manufacturing process. GnT I 
deficient cells such as CHO-gmt4 cells would produce a majority of Man5GlcNAc2 
glycosylated monoclonal antibodies and may reduce batch-to-batch variability in 
antibody production.  
 
Southern blot analysis of human genomic DNA has shown that the GnT I gene exists 
as a single copy on chromosome 5 (Hull et al., 1991). This concurs with the finding 
that in the glycosylation mutant cell lines, only one mutation has been found which 
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has rendered the GnT I enzyme inactive and homozygously null in these cells. Several 
other GnT I CHO mutants have also been found by using the lectins L-PHA (Chen, 
2002) and these cells have also been shown to contain one allele for GnT I as well. 
The mutations found from these cell lines add to a growing list of mutations that 
render GnT I partially or fully inactive, and together with the crystallographic model 
of a rabbit GnT I enzyme that has been published (Ünligil et al., 2000), give further 
insight into the structure and function of GnT I. 
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CHAPTER 5  HIGHLY SIALYLATED ERYTHROPOIETIN 
EXPRESSION IN CHO GLYCOSYLATION MUTANTS 
 
5.1  Overview 
 
The sialylation of therapeutic recombinant glycoproteins has been shown to affect the 
circulatory half-life and hence the efficacy of the recombinant protein drug. This was 
shown to be due to the presence of an asialoglycoprotein receptor that is present in on 
the surface of hepatocytes. This receptor specifically binds to N-glycans present on 
glycoproteins that have the galactose residue exposed. Upon binding to the N-glycan, 
the glycoprotein is then endocytosed and removed from circulation in the blood.  
 
In addition to the fact that GnT I restores the sialylation profile of EPO in 
glycosylation mutants isolated from RCA-I selection, it was observed that the 
sialylation was actually superior to EPO expressed in wild-type CHO-K1. This 
chapter describes how erythropoietin expressed in CHO-glycosylation mutants 
lacking GnT I are able to sialylate EPO much better in the presence of restored GnT I 
function both in transient expression and in stable expression of EPO. This superior 
sialylation is also observed in the transient expression of a fusion protein EPO-Fc. 
Purified EPO-Fc expressed in one of the glycosylation mutants with restored GnT I 
function and CHO-K1 cells is analysed and compared using HPAEC-PAD and total 
sialic acid quantification.   
5.2  Results  
5.2.1  Superior sialylation is not due to the overexpression of GnT I 
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In Fig. 5.1A, lane 1 shows the clinical EPO IEF analyses which contain only highly 
sialylated EPO bands which appear in the top half of the IEF gel. The next two lanes 
contain EPO expressed in CHO-K1 wild type cells without and with GnT I 
overexpression respectively. These two lanes do not show any difference in the IEF 
pattern. The next lane contains EPO expressed by JW152 without and with the 
overexpression of GnT I. After GnT I function has been restored to the JW152 cells, 
the EPO bands are observed to shift completely to the top half of the IEF gel, with a 
just a few more bands when compared to the clinical standard. This indicates that the 
overexpression of GnT I in CHO-K1 wild type cells does not improve the sialylation 
of EPO. However, it is observed that the overexpression of GnT I in JW152 does 
improve the sialylation of EPO. 
 
Figure 5.1 IEF of EPO expressed in CHO-K1, JW152 and Lec1 with and without 
the co-expression of GnT I. 
A) The overexpression of GnT I in CHO-K1 cells does not improve the sialylation of 
EPO. The treatment of EPO samples with neuraminidase reduces all the bands to the 
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basic portion of the gel.  B) Lec 1, a GnT I mutants, also sialylates EPO better when 
GnT I function is restored.  
 
To further show that the change in IEF pattern is due to a difference in sialylation, all 
four samples were incubated with neuraminidase. The neuraminidase cleaves both α-
2,6- and α-2,3 linked sialic acids. After incubation, the IEF bands for all four samples 
appear in the lower half of the IEF gel, with two or three bands less than the IEF 
bands for EPO expressed in JW152. This indicates that the different bands that appear 
in the upper half of the IEF gel contain sialic to certain extents, and lead to different 
EPO isoforms with isoelectric points. The extra bands that appear in the JW152 
sample without GnT I overexpression could possibly be due to presence of sialic acids 
that are attached to the O-glycan.  
 
Lec1 cells isolated from lectin selection using L-Pha were also found to be deficient 
in GnT I function and contain the same genetic mutation as KFC-8. Fig. 5.1B shows 
the IEF analysis of transiently expressed EPO in Lec1 cells with and without the 
restoration of GnT I function. Similar to the IEF of EPO expressed in JW152, the 
EPO bands appear in the lower half of the blot before restoration and only in the 
upper half after GnT I function is restored. This might indicate that the general 
property of GnT I deficient cells is to be able to sialylate well once the GnT I function 
is restored though overexpression. Subsequently, EPO was transiently expressed in 
the other nine distinct mutants as described in chapter 4. In Fig. 4.5, we observed that 
not only was the sialylation restored after overexpressing GnT I, it is observed that the 
EPO bands are all similarly concentrated in the top half of the IEF gel, indicating that 
the EPO is better sialylated. 
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5.2.2  IEF blot of transiently expressed EPO-Fc with and without GnT I 
function restoration 
 
CHO-K1 and JW152 cells were transiently transfected EPO-Fc with and without the 
restoration of GnT I function and analyzed with IEF. Fig. 5.2 is an IEF blot of cell 
culture supernatant containing transiently expressed EPO-Fc. The same pH gradient is 
used in the IEF gel and for CHO-K1 cells, the EPO-Fc expressed is concentrated in 
the middle region of the gel, whereas EPO-Fc expressed in JW152 without GnT I co-
expression is right at the bottom of the blot. Upon co-expression with GnT I, the 
EPO-Fc bands were found to be concentrated at the top half of the blot. Furthermore, 




Figure 5.2 IEF analysis of transiently expressed EPO-Fc in CHO-K1 and JW152 
cells.  




5.2.3  Total sialic acid assay in purified transient EPO  
 
CHO-K1 cells were transfected with EPO-Fc and JW152 with EPO-Fc and GnT I 
expression plasmids and then cultured in protein free media to facilitate the 
purification of EPO-Fc via affinity chromatography using a protein A-linked resin. 
The purified EPO-Fc was then treated with neuraminidase to release the sialic acid 
and then the amount of sialic acid released was measured using the thiobarbituric acid 
assay. The EPO-Fc expressed in CHO-K1 yielded 0.22 µg of sialic per 3.5 µg protein  
and the EPO-Fc sample co-expressed with GnT I in JW152 yielded 0.28 µg of sialic 
per 3.5 µg protein and represents a 23% increase in sialic acid content (see Fig. 5.3). 
 
Figure 5.3 Total sialic acid quantification of EPO-Fc transiently expressed in 






Figure 5.4 HPAEC elution profile with N-linked glycans of EPO-Fc expressed in 
JW152 that was co-transfected with GnT I and in wild type CHO-K1:  
(●) galactose, (○) mannose, (□) N-acetylglucosamine, (◊) sialic acid, and (▵) 
fucose. The eluted peaks and their corresponding N-glycan structures are numbered 
accordingly. Higher proportion of tri- and tetra-sialylated glycans and lower 
proportions of mono- and di-sialylated glycans in JW152 co-expressing GnT I, 
tabulated from HPAEC elution profile. 
 
5.2.4  HPAEC profiling of EPO-Fc  
 
N-glycans were cleaved off the EPO-Fc transiently produced in CHO-K1 cells and in 
JW152 co-expressing GnT I. The N-glycans were then analyzed using HPAEC-PAD 
using the Dionex BioLC as previously described (Lim et al., 2008). Fig. 5.5 shows the 
elution profiles of N-linked glycans released from the respective EPO-Fc samples. 
Both samples have peaks in the asialo, mono (1S)-, di (2S)-, tri (3S)- and tetra (4S)-
sialylated elution regions of the chromatogram. Arrow refers to an internal control, 
raffinose, which is a trisaccharide made up of galactose, glucose, and fructose. In the 
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mono-sialylated (1S) and di-sialylated (2S) elution region, higher peaks were 
observed for the N-glycans from CHO-K1 whereas in the tri-sialylated (3S) and tetra-
sialylated (4S) elution region, higher peaks were observed for N-glycans from JW152 
cells that were co-transfected with GnT I. All known peaks are either directly 
matched to N-linked oligosaccharide standards or inferred from retention time shifts 
of the standards. Fig. 5.4 shows that the enhanced sialylation of JW152 in the 
presence of GnT I over CHO-K1 cells is a result of increased amount of sialylated 
glycan structures with higher antennary branching (3S and 4S). The areas under the 
peaks in 1S, 2S, 3S and 4S were calculated and summarized in the table in Fig. 5.5. 
These results also support the conclusion drawn from the IEF profiles in Fig. 5.2, that 
JW152 sialylates EPO-Fc better in the presence of functional GnT I than in wild type 
CHO-K1 cells. 
 
5.2.5  Stable expression of EPO in JW152 cells with restored GnT I function 
also show superior sialylation 
 
JW152 cells were transfected with pEIG plasmid to co-currently express both EPO 
and GnT I. This plasmid contains the open reading frames of EPO and GnT I 
interspersed with an internal ribosome entry site (IRES) of the encaphalomyocarditis 
virus (ECMV). As the EPO open reading frame is immediately after the CMV 
promoter, its expression would be much stronger than the expression of GnT I, which 
is driven by the IRES site. For comparison, CHO-K1 cells were also transfected with 
an expression plasmid containing the open reading frame of EPO.  
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After transfection, the cells were put under selection with G418 at 800 µg/ml for 
about two weeks, whereby the untransfected cells under the same selection were 
observed to be dead. The resulting stable pool is seeded sparsely in 6 well plates and 
individual colonies are allowed to grow before being isolated into 24 well plates.   10 
random clones from the stably transfected JW152 cells were chosen for analysis. The 
IEF analysis shown in Fig. 5.6 indicates that all ten clones express EPO with a narrow 
range of isoelectric points in the acidic region, meaning that the EPO is all well 
sialylated. Nine random clones were chosen for analysis from the stable pool of CHO-
K1 cells expressing EPO alone. Fig. 5.7 shows that the sialylation of EPO in CHO-K1 
cells varies from clone to clone. But overall, the sialylation is not as good as the stable 
clones derived from JW152.  
 
Figure 5.5 IEF analysis of stably expressed EPO from clones derived from 




Figure 5.6 IEF of stably expressed EPO from clones derived from CHO-K1 cells. 
Clonal variation in terms of sialylation is observed and overall sialylation is very 
heterogeneous.  
5.3  Discussion 
 
In the biopharmaceutical industry, mammalian cell culture systems, especially CHO 
cells, are predominantly used for the production of therapeutic glycoproteins. 
Carbohydrates linked to the glycoprotein drugs play crucial roles in protein folding, 
secretion and determining the in vivo circulation time. Therefore, proper glycosylation 
is essential for the therapeutic efficacy of a recombinant glycoprotein drug. Proteins 
such as erythropoietin (EPO), interferon-γ (IFN- γ) and Factor VIII require high levels 
of sialylation on their N-glycans as the lack of sialylation results in their rapid 
removal from the blood stream by the asialoglycoprotein receptor expressed in the 
liver (Morell et al., 1971). Consequently, less sialylated isoforms of EPO, which can 
account for up to 80% of the total product, have to be removed in the final steps of 
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purification. Therefore, the improvement the sialylation of recombinant EPO has a 
great commercial interest in the biotechnology community. Different ways to 
genetically modify the host cells or optimize the cell culture conditions to improve 
sialylation have been reviewed in (Hossler et al., 2009).  
 
It was unexpected that the expression of functional GnT I in GnT I-deficient mutant 
cells would lead to an increase in sialylation of recombinant EPO. The improved 
sialylation of a different fusion protein, EPO-Fc, in JW152 cells was also observed by 
IEF, total sialic acid quantification assay (TBA) and HPAEC. Other means of 
quantitative assessment of the extent of sialylation such as sialic acid quantification of 
EPO could have been used, but the transient expression of EPO might not be enough 
for the analysis, hence the move to use EPO-Fc as a model glycoprotein. Other 
methods to analyze glycan profile such as reverse phase-HPLC and normal phase-
HPLC which will separate glycans on the basis of their hydrophobicity and size of the 
glycan respectively. However, the methods chosen was partially due to existing 
glycan analysis platforms for swift and accurate measurement. 
 
The improvement in sialylation seems to be the result of increased amount of glycans 
with higher antennary branching (Fig. 5.5). However, the molecular mechanism for 
this improvement remains unknown. 
 
A previous work involving the overexpression of GnT IV and V in CHO cells 
producing IFN-γ (Fukuta et al., 2000a) led to the highly branched glycan structures 
observed by means of lectin blotting and high performance liquid chromatography 
(HPLC). However, the resultant glycan structures were also observed to contain 
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incompletely sialylated antennae. It is speculated that that the increased branching and 
better sialylation could be due to the upregulation of GnT IV and V in the GnT I CHO 
mutants. This upregulation might have been in response to the GnT I deficiency in 
order to make-up for deficiency. This speculation can be further investigated using 





CHAPTER 6   UTILIZING ZINC-FINGER NUCLEASE TO KNOCK OUT 
DHFR IN CHO-GMT4 CELLS 
6.1  Overview 
 
In previous chapters, we have described the generation of GnT I mutants, isolated 
from RCA-I lectin selection, that are capable of enhanced sialylation following GnT I 
restoration. One of these cells lines, JW152, now renamed as CHO-glycosylation 
mutant 4 or CHO-gmt4 cells was shown to sialylated EPO better even in stable 
expression.  But in order for this cell line to applicable to the industry, the cell line 
also needs to be capable of producing high titres of the recombinant protein. To 
generate such a line, we aimed to utilize methotrexate (MTX) amplification process to 
achieve amplification of the recombinant gene. To allow for MTX amplification, it 
was necessary to knock out the dihydrofolate reductase gene from the cell line. This 
was carried out using zinc-finger nuclease technology. CHO-gmt4 cells were 
transfected with a published pair of zinc-finger nuclease expression plasmids and 
subsequently stained for the DHFR protein and successfully knocked-out cells were 
isolated via FACS.  
 
This chapter details the generation of a DHFR-knocked out CHO-gmt4 cell line and 
the characterization of this cell line.  
6.2  Results 
 
6.2.1  Knocking out DHFR in JW152 cells (CHO-gmt4) 
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Zinc finger nuclease protein sequences were previously published and were reversed 
translated into DNA sequence using the CHO codon usage. This DNA sequence was 
incorporated into the backbone of a zinc finger architecture listed below.  
The pair of zinc finger nucleases was also cloned into pcDNA 3.1 (+) expression 
plasmids. The coding sequence is included where highlighted in yellow is the DNA-
recognition sequence and DNA sequence highlighted in blue represents the nuclease 
coding sequence. Letters in bold and underlined letter denote the sequence encoding 
the actual fingers.   
Left Finger: 
 
Finger 1:           RSDTLSE         AGGTCCGACACCCTGTCCGAG  
Finger 2:           NNRDRTK       AACAACAGGGACAGGACCAAG 
Finger 3:           RSDHLSA        AGGTCCGACCACCTGTCCGCC 























Finger 1:           QSGALAR        CAGTCCGGCGCCCTGGCCAGG 
Finger 2:           RSDNLRE        AGGTCCGACAACCTGAGGGAG 
Finger 3:           QSSDLSR         CAGTCCTCCGACCTGTCCAGG 






















CHO-gmt4 cells were plated in 6-well plates and transfected with the two expression 
plasmids using Lipofectamine 2000 as the lipofection reagent. Two days after 
transfection, cells were passaged and cultured for another two days followed by 
incubation with fluorescein-methotrexate, which stains for DHFR positive cells. Cells 
were then sorted using fluorescence-activated cell sorting (FACs) and negatively 
stained cells were pooled and cultured. Two weeks later, this pool was sorted again in 
a second round of FACs, after which single cell clones were isolated.  
6.2.2  Characterization of DHFR knock out cell line 
 
The exact DNA mutation was to be ascertained by genomic DNA and PCR 
amplification using primers specific to the zinc finger target site.  
 
The resulting PCR product of 453 base pairs using genomic DNA extract from the 
DHFR gene-targeted cells and parental JW152 was analyzed with 1.5% agarose gel 
electrophoresis and compared. The cell line being characterized, CHO-gmt4D was 
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found to have an amplicon that was about 150 base pairs longer (see Fig. 6.1). The 
DNA band was excised, purified and sent for sequencing. The sequencing 
chromatogram in Fig. 6.2 shows a single signal, which suggests that the amplicon 
contains one type of sequence. The sequencing results also showed that CHO-gmt4D 
cells were gene-edited such that the target site contained a 130 base pair insertion.  
 
2 million cells from CHO-gmt4 parental cell line, CHO-gmt4D and DG44 cells were 
lysed in 200 µL of lysis buffer. 40 µL was used for western blot analysis using 
antibodies specific for CHO-DHFR protein. DG44 cells are CHO cells which lacks 
the DHFR gene and act as a negative control. Western blot analysis (Fig. 6.4) of the 
CHO-gmt4D cell lysate showed an absence of the DHFR protein, as similarly 
demonstrated in the DG44 cell lysate. 
 
Figure 6.1 Genomic DNA PCR amplification of zinc-finger nuclease target 
region.  
The amplification of the target region in parental CHO-gmt4 cells results in an 
amplicon size of 500 base pairs. The amplicon of the PCR reactions from CHO-




Figure 6.2 Chromatogram from sequencing genomic DNA PCR amplicon of 
zinc-finger nuclease.  
The chromatogram shows a single signal, which contains an insertion of 130 base 
pairs from the first box to the second box highlighted in red.   
 
Figure 6.3 Alignment of sequencing result of CHO-gmt4D DHFR target site for 
zinc-finger nuclease.  
The alignment shows an insertion of 130 base pairs  which resulted in a frame shift in 






Figure 6.4 FACs analysis of cells stained with fluorescein-methotrexate 
 
 
Figure 6.5 Western blot of cell lysates of CHO-gmt4, DG44 and CHO-gmt4D 
showing the absence of DHFR in both DG44 and CHO-gmt4D.  
 
6.3  Discussion 
 
In order to amplify the expression of EPO in the CHO-gmt4 cell line, it was necessary 
to either knock out the glutamine synthetase gene or the DHFR genes as these are the 
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only two expression systems, which result in gene amplification with the appropriate 
selection agents. The classical way of doing a gene knock out in cells using 
homologous recombination would have required a lot of single clone screening. With 
the current technology using zinc-finger nucleases, the task of gene editing in cells 
has become easier as the chances of obtaining a successfully gene edited cell is higher.  
 
Previous efforts of isolating DHFR knocked outs cells after zinc-finger transfection 
involved the manual picking of single clones followed by staining with fluorescent 
conjugated MTX As this still represented a laborious method, the approach was 
optimized to generate a more high throughput method for isolating DHFR-knocked 
out cell lines. These efforts led to the development of a platform in our lab which 
utilizes FACS to enrich for cells that were negatively stained with F-MTX that 
specifically targets the protein of interest. This platform can be employed for the 
knock-out of DHFR in many other CHO cell lines.    
 
The process of enriching the pool of successfully gene-edited and subsequent single 
clone isolation led to characterization of CHO-gmt4D cell line that surprisingly 
contained only one allele of DHFR. The insertion of 130 base pairs in the single allele 
was shown to cause the protein to be absent as shown by western blot. It is speculated 
that the protein underwent misfolding due to the frame shift in amino acid sequence 
and might have resulted in  ER associated degradation. 
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CHAPTER 7  AMPLIFICATION OF ERYTHROPOIETIN EXPRESSION IN 
CHO GLYCOSYLATION MUTANT CELLS 
 
7.1  Overview 
 
The successful knock out of the DHFR gene in CHO-gmt4 cells gave rise to a new 
cell line, CHO-gmt4D. This chapter first describes efforts to generate a high 
producing EPO expressing stable clone through gene amplification using MTX. After 
three rounds of amplification, a series of clones were found to produce EPO with 
good sialylation. It was important to determine whether this superior sialylation could 
be maintained in an industrial bioreactor setting. One of the clones was cultured in a 5 
L perfusion bioreactor using protein-free media. The resultant EPO was purified and 
its glycosylation was then analyzed via HPAEC-PAD, total sialic quantification and 
MALDI-TOF mass spectrometry. These results were compared to an existent EPO-
producing industrial clone used in that same facility for production.  
7.2 Results  
 
 
Figure 7.1 Expression plasmid pEGD  
The coding sequences for EPO, IRESWT and GnT I were linked via overlap PCR and 
cloned into an existing expression plasmid which contained the attenuated IRES 
sequence and DHFR coding sequence downstream of the multiple cloning site.  
 
 79 
7.2.1  Stable cell line and amplification 
 
The pEGD vector (see Fig. 7.1) was constructed for the tricistronic expression of EPO, 
GnT I and DHFR driven by a single CMV promoter. In the vector, the open reading 
frames of GnT I and DHFR were linked to that of EPO by IRESwt and IRESatt (Fig. 
7.1). CHO-gmt4D cells were transfected with pEGD and then sub-cultured in IMDM 
supplemented with 10% dialyzed FBS without hypoxanthine and thymidine 
supplementation. After two weeks, single clones were isolated and eleven of them 
that expressed EPO were chosen after dot blot analysis.  Western blot analysis of EPO 
showed that 9 out of 11 clones expressed EPO with a higher molecular weight (Fig. 
7.2), suggesting the presence of restored GnT I function. EPO expressed in the other 
two clones showed the same molecular weight as that expressed in CHO-gmt4 cells 
suggesting the absence of GnT I activity. The sialylation pattern of EPO expressed in 
the 9 clones was analyzed using IEF/western blot and the results are shown in Fig. 7.2. 
Clinical EPO produced by Amgen was used as a control and shown on the far left. In 
this sample, the EPO bands are located in the acidic region of the IEF gel, suggesting 
that the EPO is highly sialylated. EPO produced by wild type CHO-K1 cells is more 
heterogeneous with bands also found in the more basic region of the IEF gel (second 
lane Fig. 7.2). The sialylation patterns of EPO produced by 9 stably transfected clones 
were all superior to EPO produced by wild-type CHO-K1 cells and they were very 
similar to that of clinical EPO (Fig. 7.2).  
 




In order to investigate whether CHO-gmt4 cells could still produce highly sialylated 
EPO after gene amplification with methotrexate (MTX), 4 stably transfected clones 
(clones 9, 13, 14 and 15 shown in Fig. 7.2) were cultured in amplification media 
containing 50 nM MTX. Two weeks later, single clones that survived 50 nM MTX 
were isolated from each of the 4 original clones. Supernatants from single cell clones 
producing the highest levels of EPO were analyzed using IEF. Clones 13-3 and 13-4 
that was isolated from original clone 13 expressed highly sialylated EPO. The other 
 
 
Figure 7.2 EPO produced by stably transfected CHO-gmt4D cells in the presence 
of functional GnT I are highly sialylated.  
Western blot analyses of EPO (upper panel) expressed in 11 stably transfected clones. 
2 out of the 11 clones produced EPO of a lower molecular weight, suggesting the 
absence of GnT I function. IEF analyses (lower panel) of supernatant containing EPO 
expressed by 9 of the stable clones in which sialylation was restored. From left: 
Amgen EPO, EPO produced by wild-type CHO-K1 cells, EPO produced by 9 stably 
transfected clones.  EPO produced by the 9 clones exhibited superior sialylation 
compared to that produced by wild-type CHO-K1 cells. 
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amplified clones had either lost functional GnT I or had decreased sialylation. Clones 
13-3 and 13-4 were chosen for further amplification with 250 nM MTX and single 
clones were isolated two weeks later. The EPO expressed by the top ten clones 
isolated from each stable population were analyzed using IEF. All 10 clones isolated 
from 13-4 cultured with 250 nM MTX displayed highly sialylated profiles (Fig. 7.3).  
The specific productivity of clone 13-4-1, shown in Fig. 2, was 2.6 times higher than 
the parent clone 13. In comparison, the sialylation patterns of EPO produced by the 
clones isolated from clone 13-3 were less superior compared to that isolated from 
clone 13-4 (data not shown). Clone 13-4-1 was named CHO-gmt4D-GnT I and was 
cultured and analyzed in an industrial bioprocess with a perfusion-based bioreactor.  
 
7.2.3  Perfusion bioreactor 
Next we investigated whether the clone, CHO-gmt4D-GnT I, was able to retain the 
superior sialylation of EPO when cultured in an industrial setting using a 5 L 
perfusion bioreactor. The bioreactor run was divided into a growth phase and a 
production phase. In the growth phase, CHO cells were introduced into the bioreactor 
where they were allowed to adhere to the Fibra-Cel® Disks by culturing them in 
DMEM/F12 media supplemented with 10% FBS. The amount of serum in the 
medium was then gradually reduced to 8% and then to 6.5%. On day ten, the cells 
were washed with phosphate buffered saline and the culture media was switched to a 
protein free CHO-S-SFM II media containing 0.5 mM of sodium butyrate for the 
production phase. A total of 94 L of media was used in the perfusion culture. The rate 
of media perfusion was regulated according to the glucose level that remained in the 
bioreactor. Fig. 7.4A shows the changes in pH value, perfusion rate and the glucose 
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concentration during the bioreactor culture with the clone CHO-gmt4D-GnT I. The 
highest perfusion rate was 10 L/day and the production phase lasted for 19 days. The 
industrial clone was cultured using the same bioreactor and the same culture process. 
 
 
Figure 7.3 EPO remained highly sialylated after MTX gene amplification.  
Clone 9, 13, 14 and 15 were treated with 50nM MTX. Two clones isolated from clone 
13, 13-3 and 13-4, produced high levels of highly sialylated EPO after the 50nM 
MTX treatment. Clones 13-3 and 13-4 were further amplified with 250 nM MTX. Ten 
single clones isolated from 13-4 after 250 nM MTX treatment, 13-4-1 to 13-4-10, 




Figure 7.4 In an industrial process utilizing a perfusion bioreactor, CHO-gmt4D-
GnT I produces better sialylated EPO than the industrial EPO-producing line. 
(A) Variation of glucose concentration, (g/L), pH and perfusion rate (L/day) during 
the bioreactor run for clone CHO-gmt4D-GnT I.  (B) IEF analyses of EPO produced 
by CHO-gmt4D-GnT I during the production phase as shown in (A). From left: 
Amgen EPO, EPO produced by CHO-gmt4D-GnT I on the corresponding days in 
production phase as specified. (C) IEF analyses of EPO produced by the industrial 
EPO-producing line (from E-Hua) during the production phase. From left: Amgen 
EPO, EPO produced by the industrial line on the corresponding days in production 
phase as specified.  
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7.2.4  IEF comparison of batch supernatant 
 
During the culture, supernatant was sampled daily from the bioreactor and the 
sialylation pattern of EPO was analyzed by IEF. As shown in Fig. 7.4B, clone CHO-
gmt4D-GnT I produced better sialylated EPO compared to that produced by the 
industrial (biosimilar) line from E-Hua Biotech Pharmaceutical Co. Ltd (Fig. 7.4C). 
In both cases, the sialylation pattern remained consistent throughout the production 
phase.    
 
7.2.5  EPO purification 
 
The purified EPO from both cell lines were also analysed using IEF. Cell culture 
supernatant containing EPO was first applied onto a column packed with CM Affi-
Gel Blue gel. Under our experimental conditions, EPO was retained in the column 
and unwanted pigments, nucleic acids and some contaminating proteins were 
removed by the washing buffer. EPO eluted from the CM Affi-Gel Blue gel column 
was purified with a DEAE Sepharose column. This DEAE Sepharose chromatography 
removed most of the impurities and EPO represents approximately 95% of the total 
protein in the eluted fraction. This partially purified EPO was further purified by a 
second DEAE Sepharose column, which removes remaining impurities and less 
sialylated EPO isoforms. This purified EPO contained only highly sialylated EPO 
isoforms, as observed in the IEF/western blot analysis of the clinical EPO produced 
by Amgen shown in Fig. 7.5 (lane 1). EPO eluted after the first DEAE Sepharose 
chromatography using IEF/western blot for both cell lines was analyzed. As shown in 
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Fig. 7.5, EPO produced by CHO-gmt4D-GnT I (lane 3) was better sialylated than that 
produced by the industrial clone (lane 2).   
 
 
Figure 7.5 Purified EPO produced by CHO-gmt4D-GnT I clone is better 
sialylated than that produced by the industrial line. 
(A) IEF/western blot analyses of purified EPO produced by the industrial line and 
CHO-gmt4D-GnT I cell line. Lane 1: Amgen EPO. Lane 2: EPO produced by the 
industrial line, purified after the first DEAE Sepharose chromatography. Lane 3: EPO 
produced by CHO-gmt4D-GnT I, purified after the first DEAE Sepharose 
chromatography. Lane 4: EPO produced by CHO-gmt4D-GnT I was purified with 
DEAE Sepharose and two extra steps, reverse phase and anion exchange 
chromatographies.  The additional purification steps did not change the sialylation 
pattern of EPO (comparing lane 3 and lane 4). (B) IEF/Coomassie blue staining of 
purified EPO samples. Lane 1: EPO produced by the industrial line, purified after the 
second DEAE Sepharose chromatography. Lane 2: EPO produced by the industrial 
line, purified after first DEAE Sepharose chromatography. Lane 3: EPO produced by 
CHO-gmt4D-GnT I, purified with DEAE Sepharose and two extra steps, reverse 
phase and anion exchange chromatographies 
 
The purification process was optimized for EPO produced by the industrial line and 
not for CHO-gmt4D-GnT I cells. As a result, the EPO produced by CHO-gmt4D-GnT 
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I was not as pure as the EPO produced by the industrial line following the first DEAE 
Sepharose chromatography. Hence, additional purification steps were performed to 
further purify the EPO produced by CHO-gmt4D-GnT I. However, no EPO was 
removed during these extra purification steps as shown by comparing lane 3 and 4 in 
Fig. 7.5. For ease of description in subsequent analyses, EPO produced by CHO-
gmt4D-GnT I that was additionally purified after the first DEAE Sepharose 
chromatography is called CHO-gmt4D-GnT I EPO.   
 
7.2.6  IEF comparison of purified EPO 
Purified EPO samples were analyzed using IEF and the gel was subsequently stained 
with Coomassie blue to visualize the protein bands. The results are shown in Fig. 3E. 
Lane 1 shows EPO produced by the industrial line that has been purified after the 
second DEAE Sepharose chromatography by E-Hua Pharmaceutical Co., Ltd. EPO 
produced by the industrial line, purified after the first DEAE Sepharose 
chromatography and CHO-gmt4D-GnT I EPO, are shown in lanes 2 and 3 
respectively. CHO-gmt4D-GnT I EPO is better sialylated than EPO produced by the 
industrial line and purified after the first DEAE Sepharose chromatography.  
 
7.2.7  Total sialic acid quantification 
To compare the sialic acid contents in the EPO produced by the two cell lines, equal 
amounts of the respective purified EPO samples were treated with neuraminidase  to 
cleave the sialic acid (Fig. 7.5, lane 2 and lane 4) before quantification using a method 
described in ( Markely et al., 2010). The results showed that the amount of sialic acid 
released from EPO produced by the industrial line was 0.25 nM/µg of protein and the 
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sialic acid content in CHO-gmt4D-GnT I EPO was 0.4 nM/µg of protein, 60% more 
than the sialic acid released from EPO produced by the industrial line (Fig. 7.6). N-
glycans released from EPO samples containing different number of sialic acid were 
analyzed using high pH anionic exchange chromatography-pulsed amperometric 
detection (HPAEC-PAD). Fig. 7.6B shows the elution profile of N-linked glycans 
released from equal amounts of EPO samples using PNGase F. Higher peaks were 
observed for N-glycans from CHO-gmt4GnT I EPO in the tri-sialylated and tetra-
sialylated glycans (Fig. 7.6B). The percentage composition of different sialylated 
glycans was calculated from the area under the curve in the different elution regions 
for both EPO samples and summarized in the table in Fig. 7.6C. This indicated that 






Figure 7.6 Sialic acid quantification and HPAEC-PAD analyses show that CHO-
gmt4D-GnT I-produced EPO is better sialylated than that produced by the 
industrial line. 
(A) The amount of sialic acid in purified EPO samples produced by two different cell 
lines were compared. CHO-gmt4D-GnT I EPO sample (as shown in Fig. 7.5, lane 4) 
contained 0.40 nM sialic acid/µg of purified protein, EPO produced by the industrial 
line (as shown in Fig. 7.5, lane 2) contained 0.25 nM sialic acid/µg of purified protein. 
(B) HPAEC-PAD elution profile of N-glycans released from EPO produced by the 
industrial line (as shown in Fig. 7.5, lane 2) and CHO-gmt4D-GnT I (as shown in Fig. 
7.5, lane 4). The elution regions denoted by 0S, 1S, 2S, 3S and 4S correspond to 
peaks with asialylated, mono-, di-, tri- and tetra-sialylated glycans. (C) The 
percentages of each glycan structures were tabulated from the elution profile. A 
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higher proportion of tri- and tetra-sialylated glycans were found in EPO purified from 
the CHO-gmt4D-GnT I clone, compared to that produced by the industrial line. 
 
7.2.8  MALDI-TOF structural glycan analysis 
 
The N-glycans released from the EPO samples were also analyzed by MALDI-TOF 
mass spectrometry to provide detailed description and quantification of glycans found 
in the EPO produced by both cell lines. EPO produced by the industrial line and 
CHO-gmt4D-GnT I that was purified using the first step of DEAE Sepharose 
chromatography was treated with PNGase F to release N-glycans. O-glycans were 
released using reductive elimination. Glycans were then permethylated and analyzed 
by MALDI-TOF in positive reflectron mode. The results are shown in Fig. 7.7A and 
B. In the mass spectrum for EPO produced by the industrial line (Fig. 7.7A), the 
peaks corresponding to di-sialylated, tri-sialylated and tetra sialylated peaks are 
highlighted in red. The glycans from EPO produced by the industrial line have almost 
comparable abundance of each species of di-sialylated, tri-sialylated and tetra 
sialylated glycans. In contrast, the major peaks found in CHO-gmt4D-GnT I EPO are 
tetra-sialylated glycan species with very low abundance in di-sialylated and tri-
sialylated glycans (Fig. 7.7B). It was also observed that in CHO-gmt4D-GnT I EPO, 
there was a greater abundance of tetra-sialylated glycans with 1-2 additional LacNAc 
units (m/z 5035.9, 5485.1 in Fig. 7.7B). The O-linked glycosylation for both samples 
were largely similar, with the major species being mono- and di-sialylated O-glycans 
(Fig. 7.7C and 7.7D). This suggests that the improvement in sialylation in CHO-
gmt4D-GnT I EPO, as seen in the various analyses, can be attributed to the increased 









Figure 7.7 MALDI-TOF analyses of N- and O-glycans released from purified 
EPO samples.  
(A) MALDI-TOF spectrum of N-glycans released from EPO produced by the 
industrial line (as shown in Fig. 7.5, lane 2). Peaks are highlighted in red for 
comparison. (B) MALDI-TOF spectrum of N-glycans released from EPO produced 
by CHO-gmt4D-GnT I (as shown in Fig. 7.5, lane 4). (C) MALDI-TOF spectrum of 
O-glycans released from EPO produced by the industrial line (as shown in Fig. 7.5, 
lane 2) (D) MALDI-TOF spectrum of O-glycans released from EPO produced by 
CHO-gmt4D-GnT I (as shown in Fig. 7.5, lane 4).  
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7.3  Discussion 
 
Sialylation of therapeutic glycoproteins has been shown to affect their circulatory 
half-life and this has been demonstrated in EPO. An in vivo study in mice showed that 
fully sialylated EPO had a circulatory half-life of 30 minutes whilst that of asialylated 
EPO was reduced to 6 minutes (Fukuda et al., 1989). It has also been shown in mice 
that the efficacy of EPO varied with the number of sialic acids on the EPO molecule. 
The isoform that contained 14 sialic acids showed the greatest efficacy (Egrie and 
Browne, 2000). Consequently, commercially available recombinant human EPO 
contains only isoforms with 9-14 sialic acid residues. EPO isoforms with less sialic 
acid have to be removed during the purification process, which can amount to as 
much as 80% of purified EPO (see review by(Grabenhorst et al., 1999)). We had 
previously shown that CHO-gmt4 (JW152) cells that lack functional GnT I gene 
produced highly sialylated EPO if the GnT I gene is reintroduced into the cells.  In 
this study, we wanted to determine whether the superior sialylation would be 
maintained after gene amplification. In addition, we wanted to determine whether the 
sialylation remained superior in an industrial bioreactor setting using serum-free 
medium.  
 
The DHFR gene in JW152 was interrupted using zinc-finger nucleases, creating the 
cell line CHO-gmt4D. Stably transfected clones expressing EPO and GnT I were 
isolated. The sialylation of EPO produced by these clones were shown to be superior 
to that produced by wild-type CHO-K1 cells. The CHO-gmt4D-GnT I cell line was 
cultured in an industrial perfusion-based bioprocess and we observed that EPO 
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produced by this cell line maintained its superior sialylation and the EPO was better 
sialylated than that produced by the industrial EPO-producing line. As the media 
components and downstream processes were not optimized for our EPO-producing 
line, the productivity and sialylation may be further enhanced with further 
optimization. The productivity of the clone may also be improved by further selection 
at a higher concentration of methotrexate.  
 
In addition to the IEF/western blot analyses showing the superior sialylation of EPO 
produced by CHO-gmt4D-GnT I cells, the improvement in sialylation compared to 
EPO produced by the industrial line was shown using sialic acid quantification, 
HPAEC-PAD and MALDI-TOF mass spectrometry. EPO produced by CHO-gmt4D-
GnT I had a greater amount of sialic acid content and more tri- and tetra-antennary 
glycans. It also contained a greater abundance in tetra-sialylated structures and 
contained one or two additional LacNAc units compared to EPO produced by the 
industrial line. Extra LacNAc units have been found in EPO produced by a human 
cell line using gene activation technology by Shire Pharmaceuticals. LacNAc units 
have also been found in CHO-produced EPO, NeoRecorman and Eprex (Shahrokh et 
al., 2011). Whether the presence of LacNAc units on EPO would affect the efficacy of 
the drug has yet to be established. The improvement in the sialylation of the EPO 
produced in the mutant cell line, with the particular glycan profile as exhibited in the 
MALDI-TOF may be further tested using in vivo studies with mice to test for the 
level of efficacy as well as activity.  
 
In conclusion, it has been established that CHO-gmt4 cells are able to produce highly 
sialylated EPO after methotrexate amplification. It has been further shown that the 
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superior sialylation of EPO is maintained in an industrial bioreactor culture setting. 
The results suggest that CHO-gmt4 cells can be used for the large-scale industrial 
production of EPO and possibly other therapeutic glycoproteins.  
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CHAPTER 8  CONCLUSIONS AND RECOMMENDATIONS 
 
8.1  Conclusions 
 
The purpose of lectin selection on CHO cells using RCA-I lectin was to isolate novel 
glycosylation mutants that might aid the study of glycosylation and produce 
recombinant proteins with unique glycosylation. Unexpectedly it was found that 
RCA-I was cytotoxic to wild-type cells as well as all other mutants except cells 
harboring dysfunctional GnT I.  
 
14 mutants were characterized in this study and nine unique mutants were found with 
five cell lines containing stop codon mutations whilst four cell lines contained point 
mutations rendering the GnT I enzyme partially inactive or completely inactive. 
These point mutations and their resultant effect on the activity of the enzyme provide 
data for further study into the structure and function of GnT I.  
 
The use of isoelectric focusing of cell culture supernatant containing transiently 
expressed EPO followed by western blotting has allowed for the quick assay of  
extent of sialylation and hence possible aberrations in the glycosylation pathway that 
might lead to incomplete sialylation. It has also provided a good way of assessing the 
activity of mutant GnT I in glycosylation mutants.  
 
All of the GnT I CHO glycosylation mutants show that by rescuing the GnT I 
function, transiently expressed EPO is better sialylated than wild type CHO expressed 
EPO. This better sialylation is not due to the overexpression of GnT I as the co-
 96 
expression of GnT I in wild-type CHO cells did not improve sialylation. This 
improvement in sialylation was observed in EPO as analysed in IEF. The IEF of EPO-
Fc with the co-expression of GnT I in the CHO-gmt4D cells also showed that it was 
better sialylated. This was further corroborated with the analysis of glycans cleaved 
from EPO-Fc using HPAEC which showed that the transient expression of EPO-Fc in 
rescued CHO-gmt4 cells contained a high proportion of tri- and tetra-antennary N-
glycans. Total sialic acid quantification of EPO-Fc expressed in rescued CHO-gmt4 
cells also contained 13% more sialic acid compared to wild-type expressed EPO-Fc. 
IEF. This result demonstrates that the increase in sialylation that was observed in the 
IEF was due to the sialylation of N-glycans with higher branching.  
 
10 stable cell lines of CHO-K1 that express EPO were analyzed using IEF and the 
clones showed a large variability in EPO sialylation. In contrast, nine single clones 
stably expression GnT I and EPO from CHO-gmt4 cells showed homogeneously 
superior sialylation. This leads one to conclude from the above experiments that the 
wild type CHO-K1 cells give varied sialylation due to clonal variability and that 
CHO-gmt4 cells are potentially good for industrial production of highly sialylated 
EPO.  
 
In order to create a stable cell line that produces highly sialylated EPO, zinc-finger 
nuclease technology was utilized to knock out the dihydrofolate reductase gene to 
enable subsequent amplification of EPO to achieve higher titres. Using fluorescence 
conjugated methotrexate, a FACS approach was used to isolate cells that were 
successfully gene edited after transfection of the zinc-finger nucleases. 
Characterization of the genomic DNA extract of the DHFR deficient clone showed a 
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130 base pair insertion in one DHFR allele. No other DHFR alleles could be found. 
Western blot of cell-lysate also showed that no DHFR protein could be detected, 
similar to the DG44 cell line. This new DHFR deficient cell line was named CHO-
gmt4D.  
 
A new expression plasmid bearing the coding sequence of EPO, GnT I and DHFR 
with interspersed IRES sequences was constructed and transfected into the  CHO-
gmt4D cells.  After selection, amplification using MTX and IEF analysis of different 
stable clones, a clone that could produce highly sialylated EPO was selected for to see 
whether the sialylation profile would be maintained when the cell line was cultured in 
a more industrial setting.  
 
EPO from the CHO clone cultured in the industrial perfusion based bioreactor cell 
culture was purified and analysed by IEF, HPAEC, total sialic quantification and 
MALDI-TOF mass spectrometry. IEF analyses showed that in an industrial perfusion 
based bioreactor, the EPO sialylation could still be maintained and was better than the 
industrial clone that was used in production. HPAEC of the purified EPO glycans 
revealed that there was a higher proportion of tetra and tri-antennary glycans attached 
to the EPO produced in this clone, very much like the transiently expressed EPO in 
the earlier chapter. Similarly, the total sialic acid quantification of the EPO sample 
showed a high proportion of sialic acid as compared to the industrially produced EPO 
sample which corroborates with the HPAEC and IEF analyses. Finally, mass 
spectrometry analysis of the EPO glycans also further corroborated the HPAEC data 
as a higher proportion of tri and tetra-sialylated glycan structures was found in EPO in 
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the CHO-gmt4D clone. Interestingly, CHO-gmt4D expressed EPO also contained 
more LacNAc structures.  
 
The study has demonstrated the application of a CHO glycosylation mutant in the 
production of highly sialylated EPO both in the laboratory setting as well as an 
industrial setting. This has been demonstrated with a series of analytical methods 
which show extensive characterization of the glycans that are found on the 
recombinant protein of interests.  
 
8.2  Recommendations for future research 
 
8.2.1  Expression of other recombinant therapeutics which require good 
sialylation 
 
The fact that CHO-gmt4 cells are able to sialylated EPO well after the GnT I activity 
is restored points to the possibility that other recombinant therapeutic glycoproteins 
could also be expressed in this cell line. Factor VIII is a very large glycoprotein which 
contains 25 potential N-glycosylation sites. Even the B-domain deleted form of Factor 
VIII contains six potential glycosylation sites. It has been reported that the asialo form 
of Factor has a reduction in circulatory half-life from 4 hours to 5 minutes (Sodetz et 
al., 1977). It would be interesting to examine the extent to which the sialylation can 
be improved on such a big protein molecule with so many glycosylation sites.  
 
The attempts at introducing extra glycosylation sites have also been successful in 
improving the circulatory half-life. One such example is the novel erythropoiesis 
stimulating protein (NESP), where the original EPO molecule was re-engineered to 
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contain two more glycosylation sites. Whilst the individual glycan structures have not 
been published, it would be possible that the expression of this glycoengineered 
protein might need a cell line that can sialylate it better. 
 
8.2.2  Expression of monoclonal antibodies with no fucosylation 
 
Glycan analysis of EPO-Fc expressed in CHO-gmt4 cells showed a mix of 
fucosylated and non-fucosylated glycans with four to five mannose residues capping 
the glycan. However, it has been shown in two different studies that the glycans 
present in the IgG1 Fc portion of antibodies produced in similar GnT I glycosylation 
mutants do not contain fucose (Sealover et al., 2013; Zhong et al., 2012).  
 
The characterization of cells lines that survive RCA-I selection show that only GnT I 
mutants that produce these oligomannose structures, hence existing antibody-
production cell lines may be selected for GnT I mutants that would produce the 
requisite non-fucosylated antibodies.  
 
8.2.3  Expression of glucocerebrosidase for therapeutic protein production 
 
Patients who suffer from Gaucher’s disease lack the functional enzyme, 
glucocerebrosidase, to break down glycolipids completely. As a result, the peripheral 
macrophage becomes engorged with the glycolipids that cannot be broken down. 
Hence the current treatment available for these patients is enzyme replacement 
therapy, which involves administering glucocerebrosidase to the patients so that it can 
be taken up by the peripheral macrophages through the cell-surface mannose 
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receptors. In order for glucocerebrosidase to be endocytosed by the macrophage cells, 
the recombinant therapeutic has to undergo carbohydrate remodeling through 
sequential treatment with glycosidases to trim back the N-glycan to reveal the tri-
mannosyl-core (Riske et al., 2012). This results in improvements mannose receptor 
binding, macrophage uptake and intracellular half-life and efficacy (Van Patten et al., 
2006) .  
GnT I mutant cell lines such as CHO-gmt4 are perfectly suited to produce 
recombinant glycoprotein therapeutics such as glucocerebrosidase. Although the 
resultant glycan structure is a penta-mannose structure, the take-up rate of 
glucocerebrosidase with this glycan structure has been shown to not be affected (Van 
Patten et al., 2006).  
 
8.2.4  Investigation into mechanism behind better sialylation of CHO-gmt4 in 
presence of restored GnT I function 
 
The improvement in sialylation of EPO in CHO-gmt4 after restoring GnT I function 
still remains unknown. Both Lec1 cells and all the GnT I mutants isolated from RCA-
I are able to sialylate EPO better although they were derived from different lectin 
selections. It is thus speculated that the mutant might have certain compensatory 
mechanisms in place due to its genetic deficiency in GnT I. Besides the inability to 
catalyze the attachment of GlcNAc, the other aspects of the GnT I mutant cell in 
terms of expression level of other glycosylation enzymes might differ from CHO-K1 
wild-type cells. It would be interesting to use microarrays to determine whether there 
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are any changes in mRNA expression on a global level when the GnT I dysfunction 
occurs.  
Further, the improvement in branching of N-glycans resulting in better sialylation 
leads to the speculation that the compensatory mechanism may lie in an upregulation 
of GnT IV, GnT V or both. This can be tested by performing quantitative real-time 
PCR to first test the mRNA expression and to quantify the amount of GnT IV or GnT 
V enzyme present in the cell-lysate via western blot. Activity assays for GnT IV or 
GnT V may also be set up and optimized to determine whether the glycosylation 




ADCC antibody-dependant cell-mediated cytotoxicity 
Ala  alanine 
Asn asparagine 
CH3COOH acetic acid 
CHO Chinese hamster ovary 
DEAE diethylaminoethanol  
DHFR Dihydrofolate reductase  
DMEM Dulbecco's modified eagle's media 
Dnase deoxyribonuclease 
EPO erythropoietin 
Epo-Fc erythropoietin-IgG1 Fc fusion protein 
ER endoplasmic reticulum 
FACS Fluorescence-activated cell sorting 
FBS fetal bovine serum 
Fc IgG1 constant region 
Glc glucose 
GlcNAc N-acetylglucosamine 
Gluase  glucosidase  
GnT  N-acetylglucosaminyltransferase 
HPAEC-PAD high pH anionic exchange chromatography-pulsed amperometric detection 
IEF isoelectric focusing/immunoblot 
IFN-γ Interferon-gamma 
IgG1 Immunoglobulin 1 
IRES Internal ribosome entry site 
LacNAc N-acetyllactosamine 
MALDI-TOF Matrix-assisted laser desorption/ionization-Time of Flight 
Man mannose 
Manase  mannosidase  
MTX methotrexate 
mRNA messenger ribonucleic acid 
NaOH sodium hydroxide 
 103 
Neu Neuraminidase/sialidase 
PBS phosphate buffered saline 
PCR polymerases chain reaction 
PNGase F Peptide -N-Glycosidase F 
RCA-I Ricinus communis agglutinin I 
RNAi ribonucleic acid interference 
SGC SpsA GnT I core domain 
siRNA small-interfering ribonucleic acid 
TBA Thiobarbituric acid assay 
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